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Summary 
 
Amyloid aggregation is implicated in various neurodegenerative syndromes 
including, among others, the well-known AlzheimerÕs disease, which is the 
most common form of dementia in elderly people. In this pathology, the !-
amyloid peptides (A!) are assembled in molecular aggregates evolving from 
low-oligomers, to protofibrils, fibrils and, ultimately, in structured amyloid 
plaques representing the characteristic hallmark of AlzheimerÕs disease. 
Several low molecular weight compounds interferring with A! aggregation 
are currently known, however a detailed description of their interactions at 
the molecular level is still missing. In the present study, molecular dynamics 
(MD) simulations were used in the context of three projects to investigate 
the ability and mechanism by which low molecular weight compounds 
interfere with A! amyloid aggregation. The first projects, conducted in 
collaboration with Prof. A. CarottiÕs research group at the University of Bari 
(Italy), focused on the effects of 9,10-anthraquinone (AQ) and anthracene 
(AC) on the aggregation of the A!14-20 segment, the most aggregation-prone 
sequence. MD simulations show that AQ interferes with !-sheet formation 
to a greater extent than does AC; this has been confirmed by in vitro 
Thioflavin T binding assays. A fruitful collaboration with the lab of Prof. E. 
Gazit at the Tel Aviv University gave life to the second project in which, 
taking advantage of the role of tryptophan in amyloid recognition and the 
aggregation inhibitory activity of quinonic moieties, a new hybrid molecule, 
1,4-napthoquinon-2-yl-L-tryptophan (NQTrp), was designed and tested as 
an inhibitor of A! aggregation. In silico, in vitro, in cell and in vivo models 
demonstrate NQTrp inhibitory activity toward A! oligomerization and 
fibrillization, as well as NQTrp ability in lowering A! cytotoxic effects on 
neuronal cell lines. In the third (entirely computational) project, the 
molecular interactions between NQTrp or AQ and the A!12-28 monomer 
were investigated through MD simulations. The obtained results suggest a 
relevant role of these inhibitors in promoting a conformational change in the 
A!12-28 monomer, thereby inducing the formation of a collapsed loop 
conformation that creates a binding pocket in which the inhibitor molecules 
can bind via hydrogen bond, electrostatic and van der Waals interactions. 
The atomistic descriptions provided by MD simulations in these three 
studies can represent a solid basis for the screening and design of small 
molecule inhibitors of amyloid aggregation having therapeutic potential in 
AlzheimerÕs disease. 
!
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Zusammenfassung 
 
Amyloid-Aggregation spielt in verschiedenen neurodegenerativen 
Erkrankungen eine wichtige Rolle, unter anderem bei der bekannten 
Alzheimer-Krankheit, welche die hufigste Form der Demenz bei lteren 
Menschen darstellt. 
Bei dieser Erkrankung lagern sich !-Amyloidpeptide (A!) zu molekularen 
Aggregaten zusammen, die aus Oligomeren zu Protofibrillen und Fibrillen 
und schliesslich zu strukturierten Amyloidplaquen evolvieren, die ein 
Charakteristikum der Alzheimer-Krankheit darstellen.  
Einige niedermolekulare Verbindungen, welche die A!-Aggregation stren, 
sind bekannt, aber eine detaillierte Beschreibung ihrer Wechselwirkungen 
auf molekularer Ebene steht noch aus. In dieser Studie wurden 
Molekldynamik-Simulationen (MD) in drei Projekten verwendet um 
Wirksamkeit und Mechanismus zu untersuchen, mit der diese Molekle mit 
geringem Molekulargewicht die A!-Amyloid-Aggregation beeintrchtigen 
knnen. Der Schwerpunkt der ersten Projekte, die in Kollaboration mit dem  
Arbeitskreis von Prof. A. Carotti an der Universitt Bari (Italien) 
durchgefhrt wurden, lag auf dem Einfluss von 9,10-Anthrachinon (AQ) 
und Anthrazen (AC) auf die Aggregation des A!14-20-Segments, der fr 
Aggregation am anflligsten Sequenz. MD Simulationen zeigen, dass AQ 
die !-Faltblatt-Bildung strker beeintrchtigt als AC. Dies wurde durch in 
vitro Thioflavin T Bindungsassays besttigt. 
Eine ergebnisreiche Kollaboration mit der Arbeitsgruppe von Prof. E. Gazit 
an der Universitt Tel Aviv fhrte zu einem zweiten Projekt, bei dem ein 
neues Hybridmolekl entworfen und als Inhibitor der A!-Aggregation 
getestet wurde, indem die Rolle des Tryptophans in der Amyloid-Erkennung 
und die Aggregation inhibierende Wirkung von Chinonstrukturen 
ausgenutzt wurde.  
In silico, in vitro, in cell und in vivo Modelle zeigen NQTrp inhibierende 
Wirkung auf A!-Oligomerisation und Fibrillenbildung sowie eine 
Herabsetzung der zytotoxischen Effekte von A! auf neuronale Zelllinien.  
In einem dritten, vollstndig computerbasierten Projekt wurden die 
molekularen Wechselwirkungen zwischen einer Reihe von 
Aggregationsinhibitoren und des A!12-28-Monomers mit Hilfe von MD 
Simulationen untersucht. Die Resultate lassen auf eine relevante Rolle der 
Inhibitoren bei der Promotion von Konformationsnderungen in A!12-28 
schliessen, wodurch die Bildung einer 'collapsed loop' Konformation 
induziert wird, die zur Formation einer Bindungstasche fhrt, in der die 
! "##!
Inhibitoren via Wasserstoffbrckenbindungen, elektrostatischen und Van 
der Waals Wechselwirkungen binden knnen.  
Die in diesen drei Projekten durch MD Simulationen erhaltenen atomaren 
Beschreibungen knnen eine solide Grundlage fr das Screenen und Design 
von niedermolekularen Inhibitoren der Amyloid-Aggregation mit 
therapeutischem Potenzial gegen die Alzheimer-Krankheit darstellen. 
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Chapter 1 
 
 
 
Introduction 
 
ÒIch habe mich verloren.Ó 
A. Deter 
 
The 25
th
 of November 1901, Auguste Deter was hospitalized at the 
Frankfurt Mental Institution in Germany; Dr. Alois Alzheimer and his 
assistant, Dr. Gaetano Perusini, examined and asked her many questions, 
which they again later asked to check her memory. When instructed to write 
her name, she tried to but could not and repeated ÒIch habe mich verloren.Ó 
(ÒI have lost myself.Ó)[1]. A few years later, Dr. Alzheimer gave a lecture at 
a congress in the German town of Tbingen, describing typical clinical 
characteristics with memory disturbances and showing neuropathological 
pictures with miliary bodies (plaques) and dense fibrils bundles (tangles); 
his colleague, Dr. Emil Krpelin, named the pathology of this case the 
AlzheimerÕs Disease[2].  
 
 
1.1 AlzheimerÕs disease 
 
ÒI am I plus circumstances.Ó 
J. Ortega y Gasset 
 
AlzheimerÕs disease (AD) is the most common form of dementia accounting 
for 50-60% of all cases. The prevalence of dementia is lower than 1% in 
individuals aged 60-64 years, but it shows an exponential increase with age, 
such that in people aged 85 years and older, the prevalence is around 28%. 
In 2006, there were 26.6 million known sufferers worldwide and AD is 
predicted to affect about 80 million people in 2040 due to the increases in 
life expectancy[3, 4]. 
AD is a progressive neurodegenerative disorder for which there is currently 
no cure or effective treatment. Symptoms include confusion, impaired 
judgments, memory loss, personality changes, disorentation and loss of 
language abilities[3, 4]. 
! #!
Neuropathological changes in AD patientsÕ brains include neuronal death in 
the regions related to memory and cognition, as well as the abnormal 
presence of intra- and extra-cellular protein aggregates[5, 6] known as 
neurofibrillary tangles and amyloid plaques. The precise relationship 
between protein aggregates in the brains of AD-affected individuals and 
their neurodegeneration symptoms has not yet been determined[7, 8]. The 
hypothesis that protein aggregation plays crucial role in neurodegeneration 
is based on the discovery that a gene linked to autosomal dominant familial 
AD encodes a precursor protein (amyloid precursor protein, APP) of the !-
amyloid peptide (A!)[9].  
In various organelles and on cell surfaces, the full-length APP is 
sequentially processed by at least three proteinases termed "-, !- and #-
secretases (Figure 1). APP cleavage by "- or !-secretase within the 
luminal/extracellular domain results in the shedding of nearly the entire 
ectodomain, yielding large soluble APP derivatives (called APPs" and 
APPs!, respectively) and generating membrane-tethered "- or !-carboxyl-
terminal fragments (CTFs). Following these extracellular cleavages, #-
secretase processes APP derivatives at the carboxyl-terminus of 
A! aminoacidic sequence, producing either a 3 kDa product (p3 in 
combination with "-secretase) or A! peptide (in concert with !-secretase 
cleavage), respectively, and the APP intracellular domain (AICD)[10].  
A! is an intrinsically disordered 39-, 40- 42-residue peptide of ~ 4 kDa 
(D1AEFRHDSGY10EVHHQKLVFF20AEDVGSNKGA30IIGLMVGGV39VI
A42) known as A!39, A!40 and A!42, respectively. A!39 is not toxic, while 
A!40 and A!42, the most common A! isoforms, are fibrillar components of 
AD amyloid plaques[11].  
During the last fifteen years, a working hypothesis has been developed 
implicating protein aggregation as the trigger of the cascade of events 
resulting in neurodegeneration and disease[12].  
This model, known as the Ôamyloid hypothesisÕ, has been upheld (and 
generalized to other neurodegenerative diseases characterized by protein 
aggregates, albeit of varying composition, such as ParkinsonÕs and 
Huntington diseases) with the general understanding of the protein 
aggregation process, mainly thanks to neuropathology, genetics and 
experimental and computational biophysics[8]. 
 
! $!
!
Figure 1. Schematic diagram of APP sequential processing (not drawn to scale). EC: extracellular; 
TM: transmembrane; IC: intracellular. The A! domain is highlighted in red. For simplicity, only one 
cleavage site is shown for each enzyme. This figure was taken from Zhen H. and Koo E. Molecular 
Neurodegeneration 2006, 1:5. 
 
 
1.2 Amyloid aggregation 
 
ÒEverything should be made as simple as it is, but not simpler.Ó 
A. Einstein 
 
Amyloid aggregates are fibrillar protein assemblies composed of 
polypeptide chains arranged in !-conformation, with their backbone 
perpendicular to the fibril axis[13, 14].  
They are the final results of a complex series of oligomerization and 
polymerization events[15]. Amyloid fibril formation is characterized by a 
nucleation growth mechanism (see Figure 2), which is strongly influenced 
by either peptide sequence or external conditions such as pH, temperature 
and denaturing alcohol concentration[15-22]. The time course of 
peptide/protein conversion to its fibrillar form (measured by Thioflavin T 
fluorescence, light scattering or other techniques) typically includes a lag 
phase followed by a rapid exponential growth phase[23-25]. The lag phase 
is assumed to be the time required for ÒnucleiÓ to form.  
Once a nucleus is formed, fibril growth proceeds rapidly by further 
association of either monomers or oligomers with the nucleus. The addition 
of preformed fibrillar species (ÒseedingÓ) causes the lag phase to be 
shortened or totally abolished as the aggregation rate is no longer limited by 
nucleation[23, 25].  
! %!
As regards A! aggregation, Atomic Force Microscopy (AFM) and 
Transmission Electron Microscopy (TEM) have revealed that in vitro A! 
fibrils are straight, unbranched and often twisted with diameters ranging 
from 1 to 10 nm. Morover, AFM and TEM have revealed the formation of a 
series of metastabile, non-fibrillar species. Some are in the form of spherical 
beads having a diameter of 2-5 nm, others are beaded-chains (composed of 
individual beads of 2-5 nm diameter) having a linear curly form, yet others 
appear as annular structures formed by circularization of beaded chains[26-
29]. All of these aggregates evolve to protofilaments that are the constituent 
units of mature fibrils. Protofibrils can bind Congo Red (CR) and Thioflavin 
T (ThT), and they contain an extensive !-sheet structure[29].  
During prefibrillar aggregate assembly, oligomeric species precede 
protofibril formation[30, 31]. Both A!40 and A!42 have been shown to exist 
as soluble oligomers in rapid equilibrium with the corresponding 
monomeric forms. Oligomers are composed of 2-4 and 5-6 molecules for 
A!40 and A!42, respectively, and Circular Dichroism (CD) measurements 
have revelead the disorganization of their molecular structures[31].  
A! oligomers have also been detected in the brains of AD patients[32], as 
well as in the lysates and conditioned growth media of cultured cells 
expressing APP[33, 34].  
The traditional formulation of the amyloid hypothesis pointed to the 
cytotoxicity of mature amyloid aggregates. Amyloid fibrils were believed to 
be toxic species, responsible for disrupting cell homeostasis and, thus, 
inducing apoptosis[35].  
This idea was supported by a correlation between higher levels of in vitro 
faster-fibril-forming A! mutants and an earlier disease onset, as well as 
greater cognitive impairment in mouse models[36].  
On the other hand, a more recent and broadly supported variation of the 
amyloid hypothesis identifies the oligomers as the cytotoxic species that 
might induce apoptosis by physically disrupting (i.e. piercing) cell 
membranes[37].  
Because of its complexity, a complete elucidation of amyloid aggregation 
mechanism is still missing; nevertheless, even our present knowledge is 
leading to more reliable and rational therapeutic strategies. Experimental 
and computational evidence suggest that the central hydrophobic region of 
A!14-21 is the trigger of the aggregation process[38] and that the central 
phenylalanines (Phe19 and Phe20)[39] play a relevant role in the cascade of 
events leading to the formation of A! fibrils.  
! &!
For these reasons, all of the computational studies presented herein focus on 
the central segment of A!, considered as the segment most prone to 
aggregation. 
 
!
Figure 2. Amyloid formation displays the typical kinetics of a nucleated polymerization where the 
rate limiting step for fibril formation is the creation of a nucleus. In this figure, the kinetic phases of 
fibril formation are shown. Left: nucleation (or lag phase) and elongation. In the lag phase soluble 
monomeric and/or oligomeric species are in pre-equilibrium with the nuclei, which are unstable 
species that can either progress to form fibrils or regress to soluble species. Right: steady state 
equilibrium between isolated monomers and fibrils at the end of fibrillization. Credits are due to Dr. 
R. Pellarin, whose PhD thesis this figure was taken from. 
 
 
1.3 Therapeutic strategies in neurodegeneration induced by 
amyloid aggregation 
 
ÒCorpora non agunt nisi fixata.Ó 
P. Erlich 
 
The aim of drug discovery is to use the biochemical knowledge of disease 
processes to define relevant targets for therapy. In neurodegenerative 
diseases induced by amyloid aggregation, the focus is on protein 
aggregation pathways. Neglecting !- and #-secretase inhibitors and focusing 
on the protein aggregation event, at least four different strategies have been 
proposed: 
i) decreasing expression of aggregation prone proteins; 
ii) stabilizing native protein conformations; 
iii) inhibiting protein conformational changes and aggregation; 
iv) increasing clearance of aggregates. 
Selected modern techniques of gene therapy could be envisioned as means 
to lower or prevent the expression of proteins involved in aggregation; 
! '!
while antisense oligonucleotide, stem cells and genetically engineered 
ribozyme are promising options[40-44], their effective application is still 
under development. Furthermore, until the biological function of normal 
proteins is established, lowering protein production may produce 
undesirable side effects. 
Stabilization of the native protein fold has been attempted in several protein 
aggregation diseases[45]. The rationale behind this approach is that if the 
native fold is stabilized, the propensity to undergo misfolding and 
aggregation is diminished. In AD, nicotine and cotinine have been shown to 
inhibit A! amyloid formation by specifically binding to the peptide and 
stabilizing its "-helix structure[46, 47]. 1,4-naphtoquinon-2-yl-L-triptophan 
(NQTrp)[48] and 9,10-anthraquinone (AQ)[49]) have been found to 
stabilize a collapsed loop conformation (see Chapter 3).  
Protein engineering has been proposed as an approach to create sequence-
modified proteins with higher stability, a lower tendency to aggregate and 
the ability to suppress wild-type protein aggregation[50]. Perhaps the most 
promising strategy to increase the clearance of misfolded proteins is the 
immunization approach, which has already been tested for AD[51-53]. The 
rationale is that vaccination with protein components of the aggregates can 
result in the production of antibodies and a cellular response able to remove 
the aggregation-prone proteins.  
Immunization can reduce amyloid load, cerebral damage and behavioral 
impairments in transgenic AD animal models[51, 54-58], however a clinical 
trial to evaluate the efficacy of the immunization strategy in AD patients 
had to be stopped due to several cases of meningoencephalitis[59]. 
Among the different strategies proposed against protein aggregation, the 
inhibition of structural changes involved in the formation of aggregates is 
the most attempted one, the reason being that the formation of misfolded 
monomers and oligomers is the first pathological event in the cascade 
leading to disease. There are, essentially, two classes of molecules under 
development: peptides and small chemical compounds. A successful 
strategy in identifying potential inhibitors has been the rational development 
of short peptides targeting the protein sequence involved in protein-protein 
interaction. The self-recognition domain is typically the region of the 
protein implicated in early misfolding and conformational changes.  
Different disrupting elements have been used: (1) amino-termini modified 
peptides with bulky groups sterically inhibiting protein aggregation[60], (2) 
non-natural aminoacids including "-aminoisobutyric acid[61], (3) N-
methylated peptides[62-64] and (4) !-sheet breakers[65, 66] alone or in 
combination with charged residues to reduce hydrophobic interactions 
! (!
triggering the protein aggregation[67]. A great advantage of peptidic 
inhibitors is their high inhibition potency and specificity and low toxicity; 
however, their aminoacidic nature imposes serious problems for 
administration and delivery[68]. By contrast, small chemical entities present 
the advantage of their drug-like properties (pharmacokinetics, 
bioavailability, brain uptake); they do, however, commonly have specificity 
and toxicity issues. Several low-molecular-weight compounds have been 
observed to inhibit fibril formation and toxicity[39,69-71] and, in particular, 
aromatic and heteroaromatic rings have been identified as potent inhibitors 
of amyloid aggregation[39]. As an example, indole derivatives, 
nordihydroguaiaretic acid, curcumin, rosmarinic acid and poliphenols such 
as epigallocathechin-3-gallate (EGCG) have been shown to inhibit the A! 
fibril formation[71-74] (Figure 3 reports relevant chemical structures).  
Despite the relatively high number of low-molecular-weight compounds 
able to impair the A! aggregation process, a detailed description of their 
interactions with A! monomers and oligomers has hitherto been missed. 
The main goal of the present thesis has been the investigation, at the 
molecular level, of small molecule interactions with different A! segments 
by means of the computational tools described in the next section. 
 
!
Figure 3. Chemical structures of small molecules active in preventing amyloid aggregation [71-74]. 
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1.3 Computational chemistry 
 
ÒIn theory there is not any difference between  
practice and theory, in practice there is.Ó 
Anonymous 
 
Computational chemistry and the concept of in silico experiments are, 
nowadays, an established branch of research whose contribution is 
determinant for the comprehension of many biomolecular processes. In an 
in silico experiment, a model of a real experiment is built, and observables 
are measured and compared with experimental measurements. If the model 
results agree with experiment, it can be used to make predictions. In 
particular, computational chemistry is useful to describe the following: 
i) structure and stability of molecular systems; 
ii) free-energy of different molecular system states; 
iii) kinetics of different molecular systems; 
iv) reaction processes within a molecular system. 
Molecular Dynamics (MD) is among the privileged computational 
techniques; it permits the study at atomic level of detail of complex dynamic 
processes that occur in biological systems, such as protein stability, 
conformational changes, protein folding and aggregation.  
 
 
1.4.1 Molecular Dynamics 
 
ÒEverything that living things do can be understood  
in terms of the jiggling and wigglings of atoms.Ó 
R. Feynman 
 
Molecular Dynamics (MD) is a computational technique for the simulation 
of the temporal evolution of the degrees of freedom of a molecular system. 
Since the publication of the first MD simulation of the bovine pancreatic 
trypsin inhibitor 33 years ago[75], MD has become one of the most 
important tools for understanding the basis of the relationship between 
structure and function of biological macromolecules. MD simulations can 
provide molecular detail concerning individual particle motions as a 
function of time and, thus, can be used to address specific questions about 
the properties of a model system. Of course, experimental validation plays 
! *!
an essential role: comparison of simulation and experimental data serves to 
test the accuracy of calculated results and to provide a basis for improving 
the methodology. This is particularly important as theoretical estimates of 
the simulation systematic errors of a simulation by use of empirical 
potentials (force field, see later) are difficult to quantify[76]. 
Generally, molecular simulations can be roughly classified in ab initio 
methods, which apply the principles of quantum physics, and molecular 
mechanics, which is based on classical mechanics[77]. The latter uses an 
empirical energy potential, called force field, and is the main equation 
defining a structure-energy relationship in molecular systems. Different 
force fields for protein and nucleic acids are currently in use, including 
CHARMM[78-81], AMBER[82], GROMOS[83] and OPLS[84]. The 
typical equation of the potential energy is a pairwise, conservative function: 
  E = Ecov ( r )+ Enoncov ( r ) !
where 
  
E
cov
! and!
  
E
noncov
! are the covalent and non-covalent energy terms, 
respectively and!   r ! is the!   N ! "! 3-dimensional array of atoms coordinates. 
The covalent term is the sum of bonds   b, covalent angles " , dihedral angles 
" !and improper dihedral angles " : 
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where   qi  is the partial charge of atom   i ,!   "0 !is the vacuum permittivity,   
r
ij
min 
is the equilibrium separation distance of the Lennard-Jones potential and 
  
"
ij
 
is the energy well depth, i.e., 
  
E
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( r
ij
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)= "#
ij .  
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The Lennard-Jones potential 
  
E
LJ
 is an effective pairwise function that 
mimics the van der Waals interactions, while the Coulombic potential 
  
E
C
 is 
the energy term that accounts for electrostatic attractions and repulsions 
between charges.  
The trajectories of atoms belonging to the molecular system are calculated 
by iterative numerical integration of NewtonÕs equation of motion: 
  
m
i
d
2
dt
2
r
i
= m
i
d
dt
v
i
= m
i
a
i
= F
i
( r
i
)= "#
i
E( r
i
)!
that express the relationship between the force field potential   E( r ) and the 
kinematic quantities, i.e. force F
i
, acceleration a
i
, velocity v
i
 and 
coordinates r
i  of the atom i.  
Note that in MD, observables are calculated as time averages, whereas 
experimental observables are assumed to be ensemble averages.  
This difference is only apparent as the ergodic hypothesis states that the 
time average equals the ensemble average. 
A
ensemble
= A
time
 
The basic idea is that if a molecular system is allowed to evolve indefinitely 
over time, it will eventually pass through all possible states. Therefore, it is 
of utmost importance, particularly in MD simulations of proteins/peptides 
aggregation events, to generate enough representative conformations of the 
analyzed system (sampling), such that the ergodic hypothesis is satisfied. 
Only in this case, experimentally relevant information concerning structural, 
kinetic and thermodynamic properties may be calculated. 
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1.4.2 Solvation 
 
ÒNot to be confused with Salvation.Ó 
Wikipedia 
 
Water is the main component of the biological environment in which many 
macromolecules operate. It is a complex medium whose modeling is 
particularly difficult. A common approach in MD is to employ explicit 
solvent, which consists in including, in the simulation, water molecules that 
are parametrized at the atomistic level[85]. This has the major disadvantage 
of being extremely time demanding and, thus, inefficient in the sampling of 
slow molecular events such as protein aggregation. A very good solution is 
the use of an implicit solvent (i.e. a mean field approximation of the solvent 
medium), which improves the calculation efficiency.  
In implict solvent models, the degrees of freedom of the water molecules 
are not considered in the force field; they are replaced by a potential 
depending only on the degrees of freedom of the solute[86]. Moreover, the 
lack of viscosity effects, arising from the absence of water molecules, 
reduces the overall frustration of the system and, thus, improves the 
sampling of the observed phenomenon. Several implicit solvent models 
have been adopted to approximate either the non-polar or polar 
contributions of solvation. Continuum electrostatics approaches based on 
the numerical solution of the Poisson equation reliably reproduces polar 
contributions and have been implemented in force fields[87], though they 
remain inefficient in terms of sampling. A convenient alternative is to use 
an analytical treatment of continuum electrostatics, as the Generalized Born 
(GB) approximation[88], which simplifies the electrostatic solvation energy 
to a pairwise potential. In some of the in silico experiments developed in the 
present thesis, the FACTS implicit solvent model[89] has been adopted in 
conjunction with the CHARMM force field[78, 79]. FACTS is based on the 
fully analytical evaluation of the volume and spatial symmetry of the 
solvent that is displaced from around a solute atom by its neighboring 
atoms. The two measures of solvent displacement are combined in an 
empirical equation to approximate the atom electrostatic solvation energy 
and the solvent accessibile surface area.  
  
"GFACTS = "G el ,FACTS +# S
i
FACTS
1
N
$  
While the first term yields the effective Born radius (used in the GB formula 
to calculate the solvent-screened electrostatic interaction energy), the 
! "#!
second is used to approximate the non-polar contribution to solvation (for 
further details refer to [89]). 
However, the most efficient implicit solvent models are those based on 
solvent accessibile surface area (SASA)[90-92]. These models are based on 
the idea that solvation energies are mostly defined by the first solvation 
shell and can be decomposed into atomic contributions, which are 
determined by the local solute geometry: 
  
G
solv
= "
i
S
i
i
# !
where   i  is the solute atom index,   " i  is the surface tension coefficient and   Si  
is the atomic solvent accessibile area. The solute surface (a measure of the 
water accessibility in the first hydration shell) is responsible for the main 
contributions to the solvation energies. In many of the in silico experiments 
developed in the present thesis, the SASA implicit solvent model[89] has 
been adopted. 
 
 
1.4.3 Common analysis in Molecular Dynamics 
 
ÒPrediction is very difficult, expecially about the future.Ó 
N. Bohr 
 
From the trajectory of a molecular dynamics simulation, several properties 
can be easily calculated. 
RMSD 
The Root Mean Square Distance (RMSD) between two (or a series of) 
structures, such as the protein X-ray structure and a simulation frame or two 
frames of the same time series, is defined as: 
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where   N  is the number of atoms,   xi ,   yi ,   zi , are the coordinates of atom   i  
after optimal superposition on a reference structure, 
  
x
r
,!   yr ,   zr , are the 
coordinates of atom   i  in the reference structure. RMSD expresses how 
different an object is with respect to another after the optimal superposition 
of the two. 
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Radius of Gyration 
The Radius of Gyration, or gyradius (RGYR) describes the dimension of a 
molecular system in space and is defined as: 
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where   N  is the number of atoms,   xi ,   yi ,   zi , are the coordinates of atom   i , 
  x ,   y ,   z , are the coordinates of the center of mass of the considered system. 
Secondary structure analysis 
It is useful, particularly for peptides, to analyze the regular secondary 
structures, which consist of polipeptide segments in "-helical or !-sheet 
arrangment. Given the atomic-resolution coordinates of a protein, one of the 
standard methods for assigning secondary structure to its amino acids is to 
use the DSSP (Define Secondary Structure of Proteins[93]) algorithm.  
DSSP begins by identifying the hydrogen bonds of the protein structure 
using a purely electrostatic definition. The energy is assumed to be: 
  
E = q
1
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( )332kcal / mol  
where   q1 = (±) 0.42e and   q2  = (±) 0.20e (based on the assignment of partial 
charges of -0.42e and +0.20e to the carbonyl oxygens and amide hydrogens, 
and the opposite charges to the carbonyl carbons and amide nitrogens) and 
  
r
ON
, 
  
r
CH
, 
  
r
OH
, 
  
r
CN
, are the distances between carbonyl oxygens and amide 
nitrogens, carbonyl carbons and amide hydrogens, carbonyl oxygens and 
amide hydrogens, carbonyl carbons and amide hydrogens, respectively.  
The DSSP algorithm identifies a hydrogen bond if the energy E is lower 
than -0.5 kcal/mol; it then recognizes eight types of secondary structure 
(each identified by its own symbol, i.e., G, H, I, T, B, E, S, L) depending on 
the pattern of hydrogen bonds.  
Those secondary structure types are then usually grouped into three larger 
classes: helix (G, H, I and T), strand (B, E and S) and loop (L). 
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P2 parameter  
The nematic order parameter P2 is widely used for studying the properties of 
anisotropic fluids such as liquid crystals[38, 94-97]. It is defined as: 
P 
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where ö d  (the director) is a unit vector defining the preferred direction of 
alignment and is defined as the eigenvector of the ordering matrix[97] that 
corresponds to the largest positive eigenvalue, ö z 
i
 is a suitably defined 
molecular vector, and N  is the number of molecules in the simulation box. 
In the present thesis, the molecular vector ö z 
i
 has been defined as a unit 
vector linking the peptideÕs C" and C"+2.  
The nematic order parameter P2 describes the orientational order of the 
system and discriminates between ordered and disordered conformations. Its 
minimal value depends on the number of peptides according the following 
relation 81 / 40" #N [97], while its maximal value can reach the theoretical 
value of one (in a situation of perfect order). P2 can be used to estimate and 
compare the amyloidogenic propensity of different peptide sequences.  
In the present studies, the value of P2, as adopted by Cecchini et al.[39, 97], 
is used to determine the !-aggregation stability of different A! segments in 
the presence and absence of a potential aggregation inhibitor. 
 
 
1.4.4 cut-based Free-Energy Profile (cFEP) 
 
ÒThe miracle of the appropriateness of the language of mathematics 
 for the formulation of the laws of physics is a wonderful gift 
 which we neither understand nor deserve.Ó 
E. P. Wigner 
 
Protein and peptide folding, starting from a very broad set of denatured 
conformations to a well-defined conformational state, is a very complex 
reaction governed by the free-energy surface[98].  
The simplest way to study the free-energy surface (and in particular the free 
energy barriers between different states) is to project it as a function of one 
or two order parameters, such as RMSD, RGYR or number of native 
contacts[99].  
The main disadvantage of these projections is that the essential information 
! "&!
about the free-energy surface and its barriers is lost because of the high 
number of degrees of freedom of the investigated system.  
In recent years, new approaches based on complex networks have emerged 
for studying the free-energy landscape of peptide (and protein) folding[100-
102]. Krivov and Karplus have introduced the minimum-cut procedure for 
the free-energy profile determination (cFEP) along a progress coordinate 
that preserves barriers[101].  
The input for the cFEP calculation is the network of conformational 
transitions, which is derived from the direct transitions between clusterized 
snapshots (nodes of the network) sampled at a given time interval along the 
MD simulations. The cFEP procedure uses a partition function of the 
coordinates defined by a method based on the folding probability (pfold) or 
by the mean first passage time (mfpt) to a selected node[103].  
Briefly, given a network, the partition function of a node, i, is given by 
Zi=!jcij, where cij is the edge capacity from node j to i, which is 
proportional to the number of direct transitions from j to i.  
When the nodes are partitioned into two groups, A and B, according to the 
minimum-cut procedure[101], then ZA=!i"!"#,! ZB=!i"$"# and ZAB=!i"!% 
j"$&#',!where ZA is the partition function of the region A, ZB is the partition 
function of the region B and ZAB is the partition function of the cutting 
surface (i.e., of the barrier) that divides the network nodes into A and B. 
Thus the free-energy of the barrier can be written as "G=-kTln(ZAB).  
It is possible to isolate all of the basins and barriers by iterative 
determinations of the minimum cuts between all pairs of nodes. 
In practice, to calculate the cFEP using the mfpt as progress coordinate, the 
nodes are sorted according to their value of mfpt with respect to a target 
node. For each value of mfpt (mfptcut) between zero and mfptMAX, a point (-
kTln(ZAB/Z), being Z the total number of nodes) on the cFEP can be 
calculated, where A is the set of all nodes with mfpt < mfptcut and B is the 
set of nodes with mfpt > mfptcut (see Figure 4). The cFEP method was 
previously used to accurately describe the free-energy surface of the folding 
of a !-hairpin[101], of a three-stranded !-sheet peptide[103] and of a cross-
linked peptide[104], as well as to identifying pathways and intermediates of 
amyloid fibril formation[105, 106].  
In the present thesis, cFEP has been used to characterize the A! monomer 
conformational variations in absence and presence of aggregation inhibitors 
as well as to identify their potential binding modes.  
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Figure 4. Schematic illustration of the cFEP procedure. a) Network nodes are first sorted according 
to increasing mfpt. For each mfptcut value, in the range from zero (node A) to mfptMAX, a cut value 
ZAB is computed. The set A of nodes on the left of the cut contains node A and all nodes with mfpt ! 
mfptcut, and ZA/Z is its relative partition function. The green, red and blue nodes have increasing 
values of mfpt in this simplified illustration. b) Relationship between free-energy basins and the 
cFEP. Solid circles represent basins, while concentric dashed circle represent values of mfpt. To plot 
the cFEP, "G=-kTln(ZAB/Z) is calculated as a function of ZA/Z. Basins 1 and 2 overlap on the one-
dimensional cFEP because they have the same mfpt distance from the native state and are therefore 
not seperated; they are both located in the first minimum of the profile after the first, (i.e. unfolding) 
barrier. This figure was taken from Muff S. and Caflisch A. J Chem Phys 2008, 130:125104-1-11. 
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Abstract: Amyloid aggregation is linked to a number of neurodegenerative syndromes, the most
prevalent one being Alzheimer’s disease. In this pathology, the b-amyloid peptides (Ab) aggregate into
oligomers, protofibrils, and fibrils and eventually into plaques, which constitute the characteristic
hallmark of Alzheimer’s disease. Several low-molecular-weight compounds able to impair the Ab
aggregation process have been recently discovered; yet, a detailed description of their interactions
with oligomers and fibrils is hitherto missing. Here, molecular dynamics simulations are used to
investigate the influence of two relatively similar tricyclic, planar compounds, that is, 9,
10-anthraquinone (AQ) and anthracene (AC), on the early phase of the aggregation of the Ab
heptapeptide segment H14QKLVFF20, the hydrophobic stretch that promotes the Ab self-assembly.
The simulations show that AQ interferes with b-sheet formation more than AC. In particular, AQ
intercalates into the b-sheet because polar interactions between the compound and the peptide
backbone destabilize the interstrand hydrogen bonds, thereby favoring disorder. The thioflavin
T-binding assay indicates that AQ, but not AC, sensibly reduces the amount of aggregated Ab1–40
peptide. Taken together, the in silico and in vitro results provide evidence that structural perturbations
by AQ can remarkably affect ordered oligomerization. Moreover, the simulations shed light at the
atomic level on the interactions between AQ and Ab oligomers, providing useful insights for the
design of small-molecule inhibitors of aggregation with therapeutic potential in Alzheimer’s disease.
Keywords: molecular dynamics; implicit solvent; Alzheimer’s disease; 9,10-anthraquinone; amyloid;
aggregation inhibition
Introduction
Fibrillar aggregation and plaques deposition of the b-
amyloid peptide (Ab) in the brain are common hall-
marks of Alzheimer’s disease. The Ab peptide is a 39-
to 43-residue segment generated by proteolysis of the
amyloid precursor protein. Although little is known on
the link between the aggregation mechanism and neu-
rotoxicity,1 experimental evidence indicates that solu-
ble oligomers and fibrillar precursors of Ab may be the
neurotoxic species.2
Abbreviations: Ab, b-amyloid peptide; AC, anthracene; AQ,
9,10-anthraquinone; MD, molecular dynamics; ThT, thioflavin T.
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Several therapeutic strategies have been suggested
for blocking different key-steps in the amyloid aggre-
gation process, including the direct inhibition of the
aggregation by using either peptides or small mole-
cules.3,4 N-methylated peptides5,6 and L/D-polypep-
tides7 were shown to block Ab aggregation. Several
nonpeptidic low-molecular-weight molecules were
observed to reduce Ab fibril formation and cytotoxic-
ity,8–10 in particular, scaffolds with aromatic or hetero-
aromatic rings have been identified as potent inhibi-
tors of amyloid aggregation.11 As an example, indole
derivatives inhibited fibril formation of Ab peptide12
and lysozyme.13 Rifampicin and p-benzoquinone
reduced the toxicity of islet amyloid peptide aggre-
gates14 as well as inhibited amyloid fibril formation of
hen egg-white lysozymes.15 Anthraquinones were
shown to be effective inhibitors of tau protein aggrega-
tion.16 Notably, some small molecules active in vitro
also showed beneficial activity against Alzheimer’s dis-
ease in a mouse model.17
Molecular dynamics (MD) simulations have shed
light on the very early events of amyloid aggrega-
tion.18–28 These studies have focused on the driving
forces governing the b assembly, emphasizing the role
of aromatic packing,19 hydrophobic forces20,21,23,27 and
electrostatic interactions.20 The arrangement of pepti-
des within oligomers and the process of reorganization
have also been investigated by MD studies.18,19,22,24,26
Moreover, the crucial role of amino acid sequence in
determining the propensity to form aggregates has
been studied in detail.23,29 Recently, based on simula-
tions of the inhibition of Ab16–22 fibrillation by a N-
methylated peptide, it has been postulated that the in-
hibitor can bind to different sites of a preformed fibril,
and thereby perturb it via different mechanisms.30
Because of both poor oral absorption and low penetra-
tion through the blood-brain barrier, peptidic inhibi-
tors have much smaller potential as drugs than small
nonpeptidic compounds, although important excep-
tions based on nonnatural aminoacids exist.31 The
mechanism of inhibition of fibril formation by small
compounds is however still obscure.
Here, we analyze the influence of two planar and
tricyclic compounds on the early phase of ordered
aggregation of a segment of the Ab peptide that pro-
motes oligomerization. Implicit solvent MD simula-
tions are used to investigate the aggregation of three
Ab14–20 (Ac-H14QKLVFF20-NHMe) terminally blocked
heptapeptides in the presence and absence of AQ or
AC. The Ab14–20 segment is chosen because it has a
high b-aggregation propensity according to biophysical
experiments,32,33 as well as atomistic simulations29,34
and a phenomenological equation based on physico-
chemical properties of the primary structure.35 Nota-
bly, the MD simulations show that a small substitution
in molecular structure (two carbonyl groups replacing
two aromatic CH) results in significant differences in
the ability to influence early aggregation. The simula-
tion results are validated by the thioflavin T (ThT)-
binding fluorimetric assay.
Results and Discussion
Properties of Ab14–20 aggregates with and
without tricyclic compounds
During the simulation the three-peptide system
explores many different configurations, including
aggregated, disaggregated, b structures with a variety
of registers, and other spatial arrangements. The P2
order parameter (described in the Methods section)
has been adopted to monitor the degree of orienta-
tional order within the oligomers: a value close to one
corresponds to an ordered trimer, with either parallel
or antiparallel b-sheet, while a value close to zero
reflects a fully disordered system [Fig. 1(A)]. The fre-
quency histograms of P2 for the unperturbed and per-
turbed systems [Fig. 1(B)] display a prominent peak at
P2 ¼ 0.8, and a shoulder for P2 values lower than 0.5,
which includes disordered aggregates and isolated pep-
tides. The P2 value for which the three distributions
cross each other (P2 ¼ 0.665) is chosen as the cross-
over value between ordered and disordered states.
With this definition, the values of order-disorder ratio
r can be calculated (Table I). AQ perturbs the oligomer
order more than AC, suggesting that the quinonic
moiety significantly contributes to the process of
disorganization.
The frequency distribution of interpeptide interac-
tion energies [Fig. 1(C)] shows two peaks. By visual
inspection, and by comparing the energies with the av-
erage P2 [circles in Fig. 1(C)], we could assign the
oligomer structures relative to the different regions in
the energy [see insets in Fig. 1(C)]. The peak at 80
kcal/mol and the peak at 40 kcal/mol correspond to
a peptide placed in the centre and at the edge of an
ordered trimer, respectively. From the plot it is evident
that the simulations with AQ have more events with
interaction energy close to zero, originating from
unstructured peptides bound to the oligomeric or iso-
lated monomers. This indicates that the system’s order
is perturbed by AQ, which is able to intercalate into
the oligomer and influence its structure.
Binding mechanism
The interactions at the basis of the activity of AQ are
the hydrogen bonds, the aromatic contacts and, more-
over, the ability to establish a favorable interaction
between the central electron-poor quinonic ring and
the electron-rich peptidic carbonyls, which here is
called as pþd interaction (see Figs. 2 and 3). A typical
series of events leading to b structure disruption by
AQ is described in Figure 2. Once approached the
oligomer, AQ separates the ordered peptides by inter-
acting with amide hydrogens (blue dashed lines). It
then penetrates into the oligomer, interfacing the
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carbonyl oxygens (red dashed lines). The b-sheet dis-
ruption is very rapid (less than 1 ns), which is in part
a consequence of the low friction constant.
The distribution of backbone oxygens (see Fig. 3,
top) shows the enrichment of coordinated carbonyl
oxygens around the quinonic moieties of AQ with
respect to the condensed aromatic rings of AC. Being
able to coordinate two amide hydrogens, and two
backbone carbonyl oxygens at the same time, the qui-
nonic moiety plays a major role in the intercalation
into the oligomer. In this way, AQ is able to seques-
trate not only donors, but also acceptors of interchain
Figure 1. AQ hinders b-sheet formation more than AC. (A) Time series of the nematic order parameter P2 for the free system
(black), and in presence of AC (red) or AQ (blue). A similar behavior was observed in the other nine runs for each system. The
magenta arrow indicates the temporal location of the snapshots shown in Figure 2. Molecular structures of AC and AQ are
represented in the insets. (B) Distribution of the nematic order parameter P2. Values of P2 close to 0.2 and 0.8 correspond to
disordered conformations and b-sheet structures, respectively. The three distributions cross each other at P2 ¼ 0.665 (vertical
solid line), which is the threshold value that separates the ordered from the disordered phase. (C) Interpeptide interaction
energy distributions (solid lines, left y-axis; see Methods section) and average P2 as a function of interaction energy (black
circles, right y-axis). The two peaks of the energy distributions correspond to a peptide in the centre of an ordered oligomer
(about 80 kcal/mol) and a peptide at the edge of an ordered oligomer (about 40 kcal/mol). The shoulder of the energy
distribution at values of about 20 kcal/mol contains events with disordered or partially ordered oligomers. The P2 values
higher than 0.5 for interaction energy close to zero is due to the propensity of the isolated peptide for an extended
conformation. The insets in (B) and (C) are schematic pictures of the oligomer conformations. [Color figure can be viewed in
the online issue, which is available at www.interscience.wiley.com.]
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hydrogen bonds, which has three main consequences:
(1) the disruption of the local intermolecular hydrogen
bond geometry, (2) destabilization of the b-sheet struc-
ture, and (3) global disorganization of the oligomer,
that is, reduction of the total order. On the other
hand, AC is not able to interact with the peptides by
hydrogen-bonds, or pþd interactions. Hydrophobic
interactions alone are apparently not sufficient to per-
turb the ordered b architecture, as indicated by the
similar values of r of the unperturbed and AC systems.
The number of aromatic contacts between the
compounds and the phenyl rings of phenylalanine is
reported in Table I. This interaction is slightly less fre-
quent for AQ. This is due to the fact that, if compared
with AC, AQ has also the ability to interact with pep-
tide polar moieties, which are competitive with the
hydrophobic ones. These results suggest that the aro-
matic interactions alone are not sufficient to drive the
perturbation of Ab14–20 ordered oligomers, although
they may favor the encounter of the tricyclic molecule
with the peptides.
Experimental results on Ab1–40
The anti-aggregating activity of AC and AQ was deter-
mined in co-incubation experiments with Ab1–40 by
monitoring maximal ThT emission intensity over the
course of 21 days (see Methods section). As shown in
Figure 4, the amyloid aggregation obeys the character-
istic nucleation-dependent pattern, with three distinct
phases: initial nucleation (lag phase), elongation, and
Table I. Order-Disorder Ratio (r), Inhibition of Fibril
Formation, and Number of Aromatic Contacts Between
the Compounds and the Phenyl Rings of Phenylalanine
System ra
Activityb
(%)
Aromatic contactsc
(no. contacts per frame)
Unperturbed 10.2
with AC 9.9 11 0.262
with AQ 6.7 33 0.242
a Ratio between order and disorder events sampled in the tra-
jectories and estimated by Eq. (1).
b Inhibition of fibril formation measured by ThT fluorescence
at a concentration of 30 lM Ab1–40 and 100 lM AC or AQ.
c Average number of aromatic contacts between the com-
pounds and the phenyl ring of phenylalanine normalized by
the total number of frames of simulations.
Figure 2. Atomistic details of b-sheet disruption by AQ. The times of the snapshots correspond to the time interval
emphasized by an arrow in Figure 1(A). The quinonic moiety interacts with the peptide oligomer in a kind of ‘‘butter-knife’’
mechanism. AQ approaches the ordered oligomer (A) and starts to interact via hydrogen bond interactions (B and C, blue
dashed lines). It subsequently intercalates into the ordered structure via hydrogen bonds and pþd interactions (D–F, red
dashed line) and causes the disruption of the oligomer (F). [Color figure can be viewed in the online issue, which is available
at www.interscience.wiley.com.]
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equilibration. Under the present experimental condi-
tions, the system reached its final equilibration phase
after about 20 days. The shape of the curves presented
in Figure 4 indicates that the final plateau is influ-
enced by the presence of AQ and much less by AC.
The ThT fluorescence emission intensity in the co-
incubation with AQ (blue symbols) was nearly 33%
lower than with the control peptide alone (black
symbols). A significantly lower inhibitory effect, 11%
decrease of ThT fluorescence emission intensity at the
final plateau, was observed for AC (red symbols). The
different inhibitory effects of AC and AQ are consistent
with the MD simulation results (Table I). A quantita-
tive agreement is not expected because of differences
in the sequence (full-length Ab in ThT assay versus
seven-residue segment in MD), in relative mass con-
centrations, and temperature values (see Methods
section).
The elongation rate marginally decreases in the
presence of AQ, while the lag phase is not influenced
at all by AQ or AC. Yamada and coworkers showed
that nordihydroguaiaretic acid, curcumin, and rosmar-
inic acid, though reducing the amount of fibril at the
equilibrium, did not extend the length of the lag phase
in the formation of fibrillar Ab, nor the time to pro-
ceed to equilibrium.36 Recently, to explain the variable
influence of compounds on Ab42 aggregation kinetics,
a new mechanism of inhibition was suggested.37 Com-
pounds able to influence the elongation and the
steady-state, but not the lag-phase, can prevent the
self-assembly by blocking only the interstrand hydro-
gen-bond formation, in agreement with the AQ-bind-
ing mechanism discussed earlier, and not by stabiliz-
ing the nonamyloidogenic conformations of the
polypeptide.
ThT measurements alone cannot unambiguously
distinguish between inhibition of amyloid aggregation
and competition of compounds with ThT binding.
Meng et al.38 showed that it is possible to determine
whether an inhibitor is a false positive by adding the
compound to a preincubated fibril sample and mea-
suring ThT fluorescence thereafter. A fast decay
(within few minutes) of the signal indicates that the
compound is indeed competing with ThT. We meas-
ured the ThT fluorescence just after adding AQ and
AC to two preincubated Ab samples. Within few hours,
we couldn’t observe any signal decrease (data not
shown), allowing us to exclude any direct competition
between AC/AQ and ThT at the ThT-binding site.
Methods
Simulation protocol and analysis
The MD simulations were performed with the
CHARMM program.39 The peptide and compounds
were modeled using the united atoms CHARMM
Figure 3. Interactions between backbone polar groups and
AQ or AC. (Top) Positions of backbone carbonyl oxygens
and amide hydrogens that are within 5 A˚ from any atom in
AQ or AC are shown by dots to display the corresponding
coordination. Denser clouds indicate a volume with higher
coordination. (Bottom) pþd interaction scheme. Two
electron-rich (d) peptidic carbonyl oxygens interact with
both faces of the electron-poor (pþ) AQ central ring.
Figure 4. Time-dependent aggregation of Ab1–40 30 lM,
incubated in PBS (phosphate 10 mM, NaCl 100 mM, pH
7.4) at 25C and monitored by ThT fluorescence. Error bars
are standard deviations calculated from triplicate measures.
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PARAM19 force field with its default truncation
scheme for nonbonding interactions (cutoff of 7.5 A˚).
Hydration effects were accounted for by using SASA, a
solvent-accessible surface based implicit model.40 Par-
tial charges for AQ were computed with the modified
partial equalization of orbital electronegativity
(MPEOE) algorithm.41,42 To be consistent with the
united atom model, charge summation of carbon
atoms and their directly connected hydrogens was per-
formed. The results were in agreement with the origi-
nal CHARMM PARAM19 partial charges for phenylala-
nine, tryptophan and peptidic carbonyl. The difference
in electronegativity between the oxygen atom in the
peptidic moiety (partial charge: 0.55) and in the qui-
nonic central ring (partial charge: 0.51) is due to the
fact that the peptidic carbonyl is directly linked to a
nitrogen, more electron-withdrawing with respect to
the carbon atoms in the quinonic ring. There is a
favorable interaction energy of 3.6 kcal/mol between
N-methylacetamide and p-benzoquinone, computed at
low dielectric conditions (i.e., distance depending
dielectric function, without the SASA solvation contri-
bution). This value is in agreement with the 3.9
kcal/mol value obtained by ab initio QM calcula-
tions.43 To validate the parameterization of the bond-
ing energy terms, two short MD simulations were per-
formed for AQ and AC, using the SASA solvation
model. Both molecules are stable, and the average
bond distances and bond angles are comparable with
the crystallographic data.44
The simulation box was prepared by introducing
three monodispersed replicas of the same heptapep-
tide, with or without the presence of a single small
molecule (AQ or AC). The concentration ratio pepti-
de:compound of 3:1 is the minimal choice to have in-
hibitory effects and complex oligomeric structures.
Note that the mass ratio peptide:compound is about
16 for the simulation and seven for the experiments
(see ThT-Binding Assay section). To have the same
mass ratio, one would have either to halve the com-
pound concentration in the ThT assay, or to double
the number of compounds in the simulation. In the
first case the inhibition effect of AC would be unde-
tectable. In the second case the compound-compound
interactions would generate undesirable spurious
effects, which is a disadvantage if one is interested in
the oligomer–compound interaction mechanism. Sim-
ulations were carried out with periodic boundary con-
ditions at fixed peptide concentration of 4.88 mM (the
simulation box side was set to 98 A˚), using Langevin
integrator at low friction constant (0.1 ps1) and at the
temperature of 330 K, which yields reversible aggrega-
tion within a reasonable computational time. Ten, 2.5
ls long, independent simulations were run for each
system. A 2.5-ls run takes 3 weeks on a single AMD
Opteron 252 CPU at 2.6 GHz.
Order parameters are useful quantities to monitor
the structural transition within peptide oligomers.25,29
In particular, the nematic order parameter P2 allows
to measure the amount of ordered b-structure in the
system:
P2 ¼
1
N
XN
i¼1
3
2
^
zi
^
d
 2

1
2
The unit vector d^ that defines a preferential direc-
tion is the eigenvector of the order matrix that corre-
sponds to the largest positive eigenvalue. The N mo-
lecular unit vectors z^i are built joining the Ca atom of
residue i to the Ca atom of residue i þ 2 (N ¼ 3  7).
The values of P2 ranges from 0 to 1, which correspond
to complete disorder and complete order, respectively.
The complete order is achieved when all the unit vec-
tors are parallel or antiparallel, while the disorder is
obtained when none of unit vectors is parallel to any
of the others.
P2 is a value of the order parameter chosen such
that it separates the ordered from the disordered
phase. Thus, the order-disorder ratio r is defined by
the number of events where the system has a nematic
order parameter lower than P2 (disorder) and greater
that P2 (order):
r ¼
n P2 > P

2
 
n P2 < P2
  (1)
Furthermore, the activity of the compounds is
measured by calculating the interpeptide interaction
energy, which is the CHARMM nonbond energy (van
der Waals plus electrostatics) of a single peptide with
the other two, without considering the compound
molecule.
Aromatic contacts between the tricyclic com-
pounds and the phenyl ring of Phe are calculated as
follows. Given a trajectory frame, the centroids of the
three rings of AC or AQ are calculated, together with
the centroids of the six phenyl rings of Phe belonging
to the three peptides. If any compound centroid is
within 4 A˚ from any Phe centroid, then an aromatic
contact is accounted. Note that more than one aro-
matic contact can be present at the same time, because
the compounds have two sides available for the inter-
facing. The AC/AQ ratio of aromatic contacts is robust
with respect to the choice of the cutoff up to 5 A˚.
ThT-binding assay
The traditional spectrofluorimetric assay with ThT was
chosen to assess the influence of the two tricyclic mol-
ecules, AQ and AC, on the kinetic of aggregation of
Ab1–40. This technique easily enables to monitor the
formation of b-sheet structures of aggregating peptides
with ThT that leads to a marked increase of the fluo-
rescence of ThT at defined wavelengths. Nevertheless,
the b-sheet/ThT interaction is unselective and does
not discriminate among oligomers, protofibrils, and
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other transient species formed across the aggregation
pathway.
The spectrofluorimetric assay was performed
through the classical method of LeVine.45 Briefly, ThT
solution for fluorescence experiments was 25 lM in 25
mM phosphate buffer (pH 6.0). Quartz cuvette for
aggregation tests contained Ab1–40 30 lM control pep-
tide (from AnaSpec, San Jose´, CA) alone, or added ei-
ther with AC or AQ 100 lM, in phosphate buffered sa-
line (phosphate 10 mM, NaCl 100 mM, pH 7.4)
containing 20% dimethyl sulphoxide to solubilize the
test compounds. The concentration of compounds was
chosen to have the highest yield of inhibition without
precipitation effects. Samples were incubated at 25C
for 3 weeks. During this period, spectrofluorimetric
readings were made in triplicate by dilution of 30 lL
of sample in 470 lL of ThT solution at 25C. Analyses
were performed with a Perkin-Elmer LS 55 fluorime-
ter, in a 700-lL quartz cuvette, using FLWinLab soft-
ware. Parameters were fixed as follows: excitation
wavelength at 440 nm with 5-nm slit; emission at 485
nm with 10-nm slit; integration time 2 s. Plots of fluo-
rescence emission intensity versus time (see Fig. 4)
showed the typical sigmoidal curve of aggregation
kinetics. Activities were calculated as percent of inhibi-
tion of free peptide aggregation after 3 weeks.
Conclusions
In previous works, the Ab14–20 heptapeptide was
shown to have high aggregation propensity by
biophysical experiments32,33 and computational app-
roaches,34,35 suggesting a key role in the self-assembly
of the full-length Ab peptide. We have therefore
hypothesized that the perturbation of the aggregation
propensity of Ab14–20 can influence the assembly prop-
erties of the full-length Ab sequence. Here, implicit
solvent MD simulations have been used to investigate
the effect of AQ and AC on the b-aggregation of three
replicas of Ab14–20. The nematic order parameter P2
was used to monitor the perturbation extent of b-
aggregation.34 Compared with AC, which is almost
inert, AQ destabilizes the interstrand hydrogen bonds
through favorable polar interactions with the backbone
of the peptide. The quinonic moiety is able to tightly
bind peptide backbone carbonyl oxygens and amide
hydrogens through pþd interactions and hydrogen
bonds, respectively, facilitating the intercalation of
the molecule into the oligomer. The stability of the
pþd interaction46 has been previously documented in
ab initio QM calculations,43 the crystal packing of iso-
cyanurate derivatives resolved by X-ray diffractome-
try,47 and coordination of anions with electron-poor
rings.48,49
Aromatic interactions have been shown to be de-
terminant in the inhibition of fibril formation as well
as the reduction of amyloid toxicity.11 Our simulations
reveal that such interactions favor the formation of the
compound–oligomer complex, but are not sufficiently
strong to significantly perturb the b-sheet formation of
Ab14–20, as observed by comparing AC with AQ.
Perturbation of multimeric assembly is the basis
for the activity of small compounds able to inhibit
amyloid fibril formation. AQ only marginally affects
the equilibrium properties of the unperturbed oligo-
meric system, that is, it slightly increases the disor-
derer events. Coarse grained simulations50 have shown
that even a small perturbation of the polypeptide free
energy landscape, for example, a fraction of kcal/mol,
dramatically influences the kinetics and the thermody-
namics of the aggregation process. These simulation
results could explain why a small perturbation pro-
duces the macroscopic decrease of amyloid aggregation
observed in vitro in presence of inhibiting compounds.
On the other hand, the slowing down or the inhibition
of the ordered aggregation process, can multiply the
alternative pathways for the aggregation,51 increasing
the chance to create other toxic species. For this rea-
son, blocking the formation of oligomeric soluble spe-
cies at their very early stages (note that the smallest
oligomer, the Ab dimer, has been recently reported to
be synaptotoxic52) should be a viable strategy, provid-
ing that the accumulation of the Ab monomer would
not trigger any significant toxic effect.53
One of the main goals of the present work is the
understanding of the interactions between tricyclic
compounds and ordered oligomers. Knowledge of such
interactions may suggest modifications of AQ for
improving its antiaggregation activity. New functional
groups potentially able to establish additional strong
interactions with Ab could be added to the quinonic
scaffold to improve the strength of binding. Among
them, positively charged aminic groups, such as those
present in anthracyclinic and xantronic antitumor
drugs, might be selected to engage in strong ionic
interactions and hydrogen bonds with polar groups of
Ab. Indeed, some anthracyclines have shown excellent
antifibrillogenic activity.54 Moreover, pixantrone, an
antitumor drug in phase III clinical trials for the treat-
ment of relapsed or refractory indolent non-Hodgkin’s
lymphoma, showed activity and proved to selectively
target soluble low oligomers of Ab protein.55 Another
suggestion, inspired by the present simulation results,
would be to link AQ to one or both termini of a
recently discovered dipeptide inhibitor of Ab oligome-
rization.31 These experimental findings, together with
the results obtained in the present study, provide use-
ful insights for the design of new molecular entities
targeting the early steps of formation of low oligo-
meric, toxic species.
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Abstract
The rational design of amyloid oligomer inhibitors is yet an unmet drug development need. Previous studies have identified
the role of tryptophan in amyloid recognition, association and inhibition. Furthermore, tryptophan was ranked as the
residue with highest amyloidogenic propensity. Other studies have demonstrated that quinones, specifically
anthraquinones, can serve as aggregation inhibitors probably due to the dipole interaction of the quinonic ring with
aromatic recognition sites within the amyloidogenic proteins. Here, using in vitro, in vivo and in silico tools we describe the
synthesis and functional characterization of a rationally designed inhibitor of the Alzheimer’s disease-associated b-amyloid.
This compound, 1,4-naphthoquinon-2-yl-L-tryptophan (NQTrp), combines the recognition capacities of both quinone and
tryptophan moieties and completely inhibited Ab oligomerization and fibrillization, as well as the cytotoxic effect of Ab
oligomers towards cultured neuronal cell line. Furthermore, when fed to transgenic Alzheimer’s disease Drosophila model it
prolonged their life span and completely abolished their defective locomotion. Analysis of the brains of these flies showed a
significant reduction in oligomeric species of Ab while immuno-staining of the 3rd instar larval brains showed a significant
reduction in Ab accumulation. Computational studies, as well as NMR and CD spectroscopy provide mechanistic insight into
the activity of the compound which is most likely mediated by clamping of the aromatic recognition interface in the central
segment of Ab. Our results demonstrate that interfering with the aromatic core of amyloidogenic peptides is a promising
approach for inhibiting various pathogenic species associated with amyloidogenic diseases. The compound NQTrp can
serve as a lead for developing a new class of disease modifying drugs for Alzheimer’s disease.
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Introduction
Alzheimer’s disease (AD), a progressive neurodegenerative
disorder for which there is no cure or effective treatment, is the
leading cause of dementia in aged humans. Symptoms include
memory loss, confusion, impaired judgment, personality changes,
disorientation and loss of language skills [1,2]. The major
neuropathological changes in the brains of AD patients include
neuronal death, particularly in regions related to memory and
cognition and the presence of intra- and extra-cellular abnormal
protein aggregates [3,4] known as neurofibrillary tangles and
amyloid plaques, respectively. In the past several years a large
body of evidence has established a pathological role for b-amyloid
polypeptide (Ab) in AD [5–10]. Accumulating evidence indicate a
fundamental role of the early soluble oligomeric species of Ab,
rather than the mature fibrillar species, in the pathogenesis of AD
[11–15]. Yet, the molecular mechanism underlying the assembly
of the different Ab species is not fully understood. However, since
these structures self-assemble, from monomers to higher oligo-
meric or fibrillar structures in a highly ordered and efficient
manner, it is likely that specific recognition elements mediate the
process.
We and others have identified a central role of aromatic residues
in formation and stabilization of amyloid structures [16–19]. This
notion has gained direct evidence by high-resolution structural
studies [20,21], theoretical analysis and molecular dynamics
simulations [22–25]. Among the aromatic moieties, tryptophan
was ranked as the residue with highest amyloidogenic potential by
Dobson and co-workers [26] and an un-biased analysis, using
peptide array technology, has clearly indicated a significantly
higher affinity of tryptophan-modified recognition module in the
molecular association of the islet amyloid polypeptide [27].
Indeed, as expected from these findings, several small aromatic
molecules such as polyphenols [28–30] and small aromatic
peptides [31] were shown to inhibit the aggregation of several
amyloidogenic peptides. Furthermore, we have shown significant
inhibition in vitro of the Ab polypeptide by indole derivatives [32].
Moreover, we have recently demonstrated efficient inhibition of
Ab oligomerization by a short D-tryptophan-Aib dipeptide both in
vitro and in vivo [31], further underscoring the important role of
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tryptophan in the binding and inhibition of Ab. These findings
have led to the suggestion that targeting of aromatic recognition
interfaces by tryptophan could be a useful strategy for anti-
amyloid formation.
Quinones have long been known to act as inhibitors of various
metabolic pathways in the cell, to have anti-bacterial, anti-viral,
and also anti-cancer activities [33,34]. Several quinones have been
shown to be effective inhibitors of the aggregation of several
amyloidogenic proteins. For example, p-benzoquinone was
reported to reduce the toxicity of islet amyloid peptide aggregates
[35] and inhibit amyloid fibril formation by hen egg-white
lysozymes [36]. Likewise, anthraquinones were demonstrated to
be effective inhibitors of Tau protein aggregation [37]. Recently,
1,2-naphthoquinone was shown to effectively inhibit Ab42
oligomerization in vitro [38]. It appears that the asymmetric dipole
of the quinonic ring plays a central role in the interaction between
the molecule and the amyloidogenic peptides. The interactions at
the basis of the anti-amyloid activity of anthraquinone (a tri-cyclic
quinone) were recently shown to be the hydrogen bonds, the
aromatic contacts and, moreover, the ability to establish a
favorable interaction between the central electron-poor quinonic
ring and the electron-rich peptidic carbonyls [39].
Here we sought to combine the strong interaction and
recognition between tryptophan and the Ab peptide with the
documented inhibitory capability of quinones towards Ab
assembly. To that end we examined the effect of 12 different
hybrid molecules, consisting of a naphthoquinone and different
linked residues, towards Ab oligomerization and fibrillization.
Among the compounds tested the hybrid 1,4-naphthoquinon-2-yl-
L-tryptophan (termed hereafter NQTrp) [40] was found to be the
most effective.
We hypothesize that intermolecular alignment of the phenyl-
alanine (at position 19 or 20 of the Ab sequence) intercalated
between the flat electron-deficient naphthoquinone moiety and the
high electron-dense indole ring of the tryptophan, would lead to
formation of a near face-to-face stable complex. Due to near face-
to-face and edge-to-face geometry accompanied by sterical
hindrance, the intermolecular complex of the aromatic elements
effectively prevents Ab assembly. Structural analysis supports this
proposed mode of action of NQTrp. In vivo assays demonstrate
that Ab inhibition is accompanied by significant amelioration of
AD-engendered symptoms.
Results
Twelve naphthoquinone hybrid molecules were screened for
their ability to inhibit formation of Ab oligomers and fibrils in vitro
[Figure S1, Table S1]. All twelve molecules included a 1,4-
naphthoquinone, but with different residues linked to it, some
aromatic and some not. All hybrid molecules were analyzed both in
the oligomer inhibition assay and ThT fibril inhibition assay
described below for NQTrp, followed by TEM analysis (not shown).
Results of all hybrids are summed up in Table S1. They show that
NQTrp had strongest inhibition activity, towards the formation of
both Ab oligomers and fibrils. It is also apparent that both the D
isomer of NQTrp (compound IID in Table S2) and the indole
derivative (compound III) are good inhibitors. These results strongly
suggest that the linking between 1,4-naphthoquinone and a
molecule containing an indole ring is crucial for optimal inhibition.
Inhibition of toxic Ab oligomer species
The effect of NQTrp on the ability of early non-toxic
intermediate Ab oligomers (,18 kDa) to further grow into the
toxic dodecameric oligomer assemblies (,56 kDa) was analyzed
using the protocol established by Hillen and coworkers [15]. This
protocol results in the formation of SDS-stable oligomers that
display toxic effects on the long-term potentiation of cultured
neural cells [15]. For example, to evaluate the effect of NQTrp
(Figure 1A) on the transformation of the Ab into the toxic
assemblies, the inhibitor was incubated with Ab1–42 at increasing
molar ratios, and the reaction mixtures were resolved on SDS-
PAGE (Figure 1B). The results reveal dose-dependent inhibition,
by NQTrp, of the ability of Ab to assemble into toxic oligomers
(,56 kDa), inhibition was apparent at a low 5:1 (Ab1–42:NQTrp);
Figure 1. Inhibition of Ab oligomer formation in vitro. A.
Structure of 1,4-naphthoquinon-2-yl-L-tryptophan (NQTrp). B. Determi-
nation of the dose-dependent effect of NQTrp on soluble oligomer
formation. Soluble oligomers were prepared according to the method
of Barghorn et al. [15] with and without increasing concentration of
NQTrp. Ab concentration was set at 133 mM. Molar ratios of Ab:NQTrp
are indicated. The control is Ab only. C. The affinity of NQTrp towards
early oligomers was determined using fluorescence anisotropy.
doi:10.1371/journal.pone.0011101.g001
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however the inhibition profile is non linear. The decreased
inhibition effect at mid-range molar rations such as at a 1:1 ratio
may be due to a competing homomolecular noncovalent
interaction as observed for various other small molecular inhibitors
such as indole moieties and small peptides. The inhibitor appears
to stabilize the non-toxic early oligomers and inhibit their further
growth into toxic species. Complete inhibition was seen only at
molar excess of NQTrp.
Characterization of the interaction between NQTrp and
Ab
The affinity of NQTrp towards the early Ab1–42 assemblies was
demonstrated using fluorescence anisotropy assay, taking advan-
tage of the intrinsic fluorescence of the Trp-substituted quinone
and its relatively small size as compared to the Ab oligomers.
Increasing amounts of early assemblies of Ab were titrated into a
solution of NQTrp and anisotropy was determined (Figure 1C).
The affinity constant of NQTrp was estimated to be 90 nM.
Inhibition of amyloid fibril formation by NQTrp
The relative contribution of Ab fibrils versus oligomers to the
pathogenesis of AD has not been completely resolved [41]. We
therefore wanted to discern whether or not NQTrp also inhibits
the formation of mature b-amyloid fibrils. To that end we used the
Thioflavin-T (ThT) binding assay, which provides a quantitative
measure of amyloid fibril formation. Ab1–40 was allowed to form
amyloid fibrils either in the absence or in the presence of
increasing concentrations of NQTrp (Figure 2A). The process of
fibrillization was followed for several days until a plateau was
reached and its kinetics was measured. The formation of Ab fibrils
was significantly reduced in the presence of the inhibitor, even at
low molar ratios of 4:1 (Ab1–40:NQTrp). This is especially evident
after 270 hours (Figure 2B). A similar experiment using Ab1–42
resulted in IC50 of 50 nM (Figure 2E). These results clearly
indicate that the NQTrp is an effective inhibitor of Ab fibril
formation.
The morphology of the Ab fibrils formed during the course of
fibrillization was compared, in the presence and in the absence of
NQTrp, using transmission electron microscopy (TEM). Samples
were taken from the amyloid fibril formation experiment after 7
days of incubation. The fibrils formed by Ab alone were large,
broad and ribbon-like (Figure 2C). The samples containing Ab
and NQTrp showed drastic reduction of fibrils. The few fibrils that
formed in the presence of the inhibitor were much thinner and
Figure 2. Inhibition of Ab fibril formation in vitro. A. Dose dependent kinetic analysis of the inhibition of NQTrp towards fibril formation of Ab1–42
over the course of 270 hours. Ab concentration was set to 5mM. Concentrations are expressed as Ab:quinone molar ratio: Control - Ab1–42 only (¤), 1:5
(&), 1:1 (m), 2:1 (N), 4:1 (*). (CPS =Counts Per Second) B. Endpoint of ThT analysis after 270 hours. C–D. Transmission Electron Microscope images taken
from ThT analysis after 270 hours. Ab1–42 alone (C), Ab1–42with NQTrp (1:5) (D). E. Dose dependent inhibition by NQTrp of the fibrillization of Ab1–42 (ThT
assay). Concentration of Ab1–42 was set to 5uM. Control - Ab1–42 alone. An IC50 of 50nM was calculated.
doi:10.1371/journal.pone.0011101.g002
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shorter (Figure 2D). This strongly correlated with the values
observed in the amyloid fibril formation experiment.
NMR analysis of the interaction of NQTrp with Ab
To characterize the precise interaction between NQTrp and
Ab, NMR analysis was conducted. NQTrp was incubated with a
truncated fragment of Ab, Ab12–28, which is a less-aggregative
fragment, commonly used to avoid complications of oligomeriza-
tion and fibrillization during the NMR process. Ab residues 16–22
have been shown to participate in the transition into the b-sheet
secondary structure and are independently capable of forming
amyloid fibrils [42–44]. Furthermore, this short fragment of Ab
contains the central aromatic recognition motif of the polypeptide
[44].
NQTrp was titrated into Ab12–28 sample in 10 mL aliquots, in
the same solvent batch as the peptide samples, to achieve
increments of 0.11 mM of NQTrp per aliquot. After each
addition, the 1H-NMR spectrum was taken. The addition of
NQTrp to Ab12–28 in solution affected the backbone amide
chemical shifts of the peptide (Figure 3A). Changes in chemical
shift at a 2:1 molar ratio (Ab12–28:NQTrp) were compared to the
average change in chemical shift of 0.1 Hz when a 0.1 mM
aliquot of NQTrp was added as a control. These were most
evident in residues Phe20, Ala21 and Glu22, which showed
changes of 8, 5 and 3 Hz, respectively. Both Val18 and Val24, also
showed a lesser change in chemical shift of 2 Hz. Non-terminal
residues that were unaffected by the addition of NQTrp showed
mostly chemical shift deviations of less than 1 Hz. The NMR
Figure 3. NMR analysis of Ab with NQTrp. A. Amide proton chemical shifts deviations of Ab12–28 residues upon interacting with NQTrp at molar
ratio between 1:0.1 and 1:0.5 (Ab12–28:NQTrp). *Residues Lys16 and Gly25 were unresolved. B. NOE connectivity plot: NOE interactions are
proportional to the thickness of the interconnecting lines. C. Lowest energy structure generated for Ab12–28 with NQTrp (at 4:1 molar ratio). Ensemble
of 28 from 50 starting structures had a RMSD of 2.28 A˚ overall and 0.71 A˚ and 0.74 A˚ in regions 16–20 and 22–26. Residues that showed significant
deviations upon binding NQTrp are colored in green. The positive (blue) and negative (red) electrostatic potential distribution for62 kT/e is mapped
onto the structure. D. Secondary structure statistics: percentage of low energy structures in turn (black), bend (grey) or coil (white), secondary
structures.
doi:10.1371/journal.pone.0011101.g003
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experiments of NQTrp-Ab12–28 binding thus showed the most
prominent interactions in the region of Phe20 to Glu22. The
changes in chemical shift indicate altered chemical environment
either due to a direct interaction with NQTrp itself or due to a
structural change that occurs upon binding.
The structure of Ab12–28 was solved in the presence of 0.25
molar ratio of NQTrp to Ab (Table 1 and Figure 3B). The
spectrum was resolved and showed numerous interactions (Table 2,
Table S2, Figure S2 and S3). Of the 50 calculated structures
(RMSD 2.37 A˚ on the backbone), 28 had no violations and a
RMSD value of 2.28 A˚ and 9 low-energy structures were chosen
for structural analysis. (Figure S3, backbone (bb) RMSD 1.12 A˚).
These had three regions of stability (Figure 3D): Residues 14–16
(bb RMSD 0.71 A˚) showed a number of NOE interactions
between the region of His13 and His14 and Leu17; residues18–20
showed a turn including phenylalanines 19 and 20 (bb RMSD
0.12 A˚). The general structure of the ensemble showed a loose b-
hairpin with a turn at residues18–20 including phenylalanines 19
and 20 (bb RMSD 0.12 A˚). Additional regions of stability
(Figure 3D) included residues 14–16 (bb RMSD 0.71 A˚) that
showed a number of NOE interactions between the region of
His13 and His14 and Leu17; and a turn at residues 22–26 (bb
RMSD 0.0.67 A˚) that were stabilized by hydrogen bonding
between the amide proton of Ser26 and the backbone oxygen of
Asp23 in the majority of the conformations. This turn was
unexpected and may either be an artifact of working with a
truncated peptide, or part of the mechanism by which NQTrp
disrupts plaque accumulation.
Figure 3C shows the lowest calculated energy conformation
with residues Val18, Phe20, Ala21, Glu22 and Val24, colored in
green to indicate residues whose chemical shift changed upon
interacting with NQTrp. The positive (blue) and negative (red)
electrostatic potential distribution for62 kT/e is mapped onto the
structure; showing the positively charged N-terminus and Lys28,
and the negative potential in the central region of the Ab12–28
peptide.
CD characterization of the interaction of NQTrp with Ab
Samples containing Ab1–42 and NQTrp were subsequently
analyzed by Circular Dichroism (CD) to gain information on the
secondary structural changes that the early Ab species undergo
when incubated with NQTrp. Native Ab1–42 oligomers exhibit a
strong positive band around 195 nm and a negative band at
217 nm, indicating a b-sheet conformation. A dose dependent
decrease in both of these bands and a small shift in the spectrum
were evident with increasing concentrations of NQTrp, yet the
typical b-sheet spectrum is still apparent (Figure 4). This implies
that, when incubated with NQTrp, Ab retains its b-sheet
conformation, yet this conformation is gradually lost with
increasing concentrations of the naphthoquinone.
Simulation of Ab assembly with and without NQTrp
Computer simulations were carried out to further investigate the
interactions between NQTrp and Ab. We examined the influence
of NQTrp on the early phase of ordered aggregation of the central
region of the Ab peptide, focusing on the segment 14–24, centered
on Phe 19 and Phe 20. A divide-and-conquer approach [46] has
Table 1. 1H chemical shift assignment of Ab12-28.
HN Ha Hb Others
V12 3.72 2.10 CH3 c 0.89
H13 8.89 4.66 3.15 Hd2 7.24, He1 8.55
H14 8.73 4.66 3.18, 3.06 Hd1 8.49, Hd2 7.26, He1 8.56
Q15 8.59 4.28 2.02, 1.94 CH2 c 2.32, He 7.6, 6.95
K16 8.48 4.24 1.76, 1.71 CH2 c 1.41, 1.34, CH2 d 1.64, CH2 e 2.93
L17 8.32 4.31 1.56, 1.42 CH c 1.56, CH3 d 0.89, 0.82
V18 7.96 4.01 1.88 CH3 c 0.79, 0.72
F19 8.21 4.54 2.96, 2.85 CH2 d 7.30, He7.28, Hf7.14
F20 8.14 4.54 3.09, 2.93 CH2 d 7.33, He7.31, Hf7.22
A21 8.26 4.19 1.33
E22 8.28 4.24 2.04, 1.91 CH2 c 2.35
D23 8.39 4.65 2.78, 2.67
V24 8.07 4.11 2.14 CH3 c 0.92, 0.91
G25 8.50 3.94
S26 8.13 4.42 3.84
N27 8.45 4.70 2.80, 2.73 CH2 d 7.61
K28 7.87 4.13 1.80, 1.67 CH2 c 1.35, CH2 d 1.62, CH2 e 2.96, Hf2 7.54
NQTrp 7.04 4.23 3.51, 3.26 CH2 d 7.26, He1 10.18, He3 7.63, Hg1 7.13,
doi:10.1371/journal.pone.0011101.t001
Table 2. NOE interaction statistics.
Total number of restraints 177
Intra-residual restraints 52
i+1 restraints 74
i+2 restraints 25
i+3 restraints 18
Long range restraints 8
doi:10.1371/journal.pone.0011101.t002
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been adopted to efficiently sample the conformational transitions
of the system. Therefore, the segment was decomposed into three
overlapping heptapeptides: Ab14–20, Ab16–22, and Ab18–24 (see
sequences in Table S3). Implicit solvent molecular dynamics (MD)
simulations were used to simulate the aggregation of three replicas
of the considered peptides in presence and absence of NQTrp.
During the simulations the three-peptide system explores several
configurations. The P2 order parameter (described in Materials
and Methods) has been adopted to monitor the degree of
orientational order within the oligomers: a value close to one
corresponds to an ordered trimer, with either parallel or
antiparallel b-sheet, while a value close to zero reflects a fully
disordered system. The frequency histograms of P2 for the
unperturbed and perturbed systems (Figure 5) display a prominent
peak at P2=0.8, and a shoulder for P2 values lower than 0.5,
which includes disordered aggregates and isolated peptides. The
Figure 4. CD studies of Ab with NQTrp. CD spectrum of Ab1–42. Concentration indicated as Ab:NQTrp molar ratio. Control - Ab1–42 only (black),
1:60 (grey), 1:30 (blue), 1:1 (orange), 5:1 (red).
doi:10.1371/journal.pone.0011101.g004
Figure 5. NQTrp hinders b-sheet formation. Red lines and black lines correspond to simulations with and without NQTrp, respectively. (Top)
Frequency histograms of the nematic order parameter P2 for the three Ab segments. Values of P2 close to 0.2 and 0.8 correspond to disordered
conformations and b-sheet structures, respectively (see the insets in the top right plot). The presence of NQTrp sensibly increases the amount of
disordered structures for all peptides. (Bottom) Inter-peptide interaction energy distributions. The two peaks of the distributions correspond to a
peptide in the center of an ordered oligomer (about 280 kcal/mol) and a peptide at the edge of an ordered oligomer (about 240 kcal/mol). The
shoulder of the energy distribution at values of about 220 kcal/mol contains events with disordered or partially ordered oligomers (see insets in the
bottom right plot). NQTrp markedly increases the amount of structures with unfavorable inter-peptide interaction energy.
doi:10.1371/journal.pone.0011101.g005
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threshold value P2
*=0.665 is chosen as the crossover between
ordered and disordered states (see Materials and Methods) [39].
The ratio between order and disorder clearly shows that NQTrp
perturbs the order of the aggregate (Table S3) by increasing the
population of disordered conformations for all three peptides. The
frequency distribution of inter-peptide interaction energies
(Figure 5) shows two peaks. The peak at 280 kcal/mol and the
peak at240 kcal/mol correspond to a peptide interacting with the
center and at the edge of an ordered trimer, respectively. From the
plots it is evident that the presence of NQTrp increases the
number of events with interaction energy close to zero, originating
from unstructured peptides bound to the oligomeric or isolated Ab
species. The presence of NQTrp alters the number of backbone
hydrogen bonds by increasing the intra-chain and decreasing the
inter-chain interactions (Table S3). The simulation results indicate
that the trimer structure is perturbed by NQTrp, which is able to
intercalate into the oligomer and influence its structure, supporting
the evidence attained above by NMR and CD spectroscopy.
Binding mechanism of NQTrp to Ab by computational
analysis
Further computational analysis was conducted in order to
determine the binding mechanism of NQTrp to Ab. Hereafter,
the hydrogen bonds between NQTrp and the Ab peptide backbone
will be identified using the labels of polar groups of NQTrp (see inset
of Figure 6 for the labels), e.g., NH1-CO is the hydrogen bond
between NH1 group and any carbonyl group of the backbone.
Furthermore the interaction with a certain residue will be specified
with the amino acid name, e.g., NH1-Phe20 is the hydrogen bond
between NH1 group and backbone carbonyl of Phe20, and CO1-
Phe20 is the hydrogen bond between CO1 group and Phe20
backbone amide. Due to the symmetry of the carboxyl oxygens of
NQTrp, the hydrogen bond that can be formed with one of the two
CO moieties will be referred as to CO3-NH. The frequency of
hydrogen bond formation between the carbonyl groups of NQTrp
and the amide backbone is shown in Figure 6. The agreement with
the NMR amide proton chemical shift deviations is remarkable.
The backbone amides that interact most with NQTrp through
hydrogen bonds belong to Phe20, Ala21, and Glu22. It is worth
noting that, although the van der Waals interaction energies
between NQTrp and Phe19 or Phe20 are very similar, there is a
much higher propensity for NQTrp to form a hydrogen bond with
Phe20. The most frequent hydrogen bonds involving the peptide
backbone are NH1-CO, CO1-NH and CO3-NH (Figure S4, Table
S4). Interestingly, the hydrogen bond pairs NH1-CO, with CO1-
NH or CO3-NH occur simultaneously at high probability (about
10% of the trajectory), and very frequently the three hydrogen
bonds are formed at the same time (5% of the trajectory) (Table S5).
These hydrogen bonds occur either within the same residue (Phe20
or Ala21), or within two amino acids that are separated by a single
residue (Val18, Phe20, or Phe20, Glu22) (Table S5).
Notably, the MD simulations show that NQTrp strongly perturbs
the ordered aggregation of the Ab peptides by binding with specific
hydrogen bonds and aromatic interactions. The snapshots shown in
Figure 7 were extracted from the trajectories according to the most
frequent hydrogen bond pairs (See Methods). In the most frequent
binding patterns, NQTrp has a closed conformation in which the
indole and the naphthoquinone ‘‘clamp’’ the phenyl rings of Phe19 or
Phe20 (Figures 7A–C). In addition, there are stable hydrogen bonds:
CO1-Ala21, and NH1-Ala21 (Figures 7A and B), or CO1-Phe20,
Figure 6. Computer analysis of the interactions between
NQTrp and Ab. Frequency of interactions between all NQTrp CO
groups and peptide backbone NHs (left y-axis). Open symbols
correspond to residues proximal to the N-terminal or C-terminal of
the peptide (positions 1, 2, 6, and 7 in each heptapeptide). Closed
symbols correspond to the central residues (positions 3, 4, and 5).
Average van der Waals interaction energy between the residues and
NQTrp are shown by blue triangles (right y-axis). Lower values
correspond to more favorable interaction energy.
doi:10.1371/journal.pone.0011101.g006
Figure 7. Modeling of representative snapshots of the binding
modes of NQTrp to the Ab_peptide. (A,B) The two most frequent
conformations (12% and 9%) when NQTrp is bound to Ab18–24
through CO1-NH and NH1-CO interactions with Ala21. The main
difference between the two structures is the swap of Phe20 and Phe19
as a counterpart for aromatic interactions with NQTrp. C The most
frequent conformation (17%) obtained when NQTrp is bound to Ab18–
24 and is involved in CO1-NH and NH1-CO interactions with Phe20. To
emphasize the aromatic interactions of the naphthoquinone and the
indole moieties of NQTrp with the phenyl ring of Phe19, a lateral view
of the conformation c. is shown in the inset. D The most frequent
conformation (11%) when NQTrp is bound to Ab16–22 through CO1-
NH with Phe20 and NH1-CO with Val18. Here the indole of NQTrp
interacts with Val18, and naphthoquinone with Phe19. See inset of Fig. 5
for the labeling of the polar groups.
doi:10.1371/journal.pone.0011101.g007
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NH1-Phe20 and CO3-Glu22 (Figure 7C). In this case Phe19
interacts with both aromatic groups of NQTrp as well. Conversely, in
the presence of the NH1-Val18 and CO1-Phe20 hydrogen bonds,
the indole and naphthoquinone moieties do not act as ‘‘clamp’’ but
rather interact with the Val18 and Phe19 side chains, respectively
(Figure 7D). Note that in all cases aromatic stacking and hydrogen
bonds with polar groups of the backbone are present.
NQTrp inhibits the cytotoxic effect of Ab towards
cultured cell line
To further substantiate the inhibition by NQTrp we tested
whether it affects the cytotoxicity of Ab1–42 oligomers towards the
rat PC12 neuronal cell line. Toxic Ab oligomers were incubated
with increasing concentrations of NQTrp and cell viability was
measured using the MTT assay. While showing no toxic effect of
its own towards cultured cells (Figure S5), NQTrp significantly
inhibited the cytotoxic effect of the Ab oligomers and caused a
significant dose dependent increase in the viability of the cells
(Figure 8A). This effect was most apparent at molar excess of
NQTrp which correlates with results attained from the inhibition
of toxic Ab oligomers analysis.
The effect of NQTrp in an in vivo transgenic fly system
In order to assess the effect of NQTrp on Ab in the living
organism, we used a Drosophila model of AD. Transgenic flies
expressing the human Ab1–42 protein in their nervous system, via
the Gal4-UAS system, display various symptoms reminiscent of
AD including defective locomotion, and memory, which deteri-
orate with age, as well as markedly reduced longevity. Their brains
display characteristic amyloid plaques and pathology [47].
Crossing male flies carrying the pan-neuronal elav-Gal4 driver (on
their X chromosome) with females homozygous for the autosomal
UAS-regulated Ab1–42 transgene, resulted in female offspring
expressing Ab1–42 in their nervous system. The male offspring carried
the Ab1–42 transgene but did not express it because they lacked the
Gal4 driver and served as control. This cross was performed either on
regular Drosophila medium or on medium supplemented with
0.75 mg/mL NQTrp. The animals fed on the appropriate medium
from the beginning of the larval stage onwards. Each class of adult
offspring was monitored daily for survival and locomotion (climbing).
Flies expressing the Ab1–42 transgene grown on regular medium
exhibited a significantly shorter life span than the control (male)
classes, as reported [47]. By day 16, only 50% of the flies expressing
the Ab1–42 transgene, were viable, while in the control class viability
was reduced to 50% only after 26 days. The life span of Ab1–42-
expressing flies reared on medium containing NQTrp (Figure 8B) was
much longer and was nearly identical to that of control flies grown on
regular medium (50% viability observed only at day 26). The
compound had no significant effect on longevity of the control flies.
Statistical analysis was performed using the SPSS 15 Kaplan-Meier
software package. Results show a significant difference between flies
(females) expressing the Ab1–42 transgene grown on regular medium
versus medium supplemented with NQTrp (P,0.0005). In contrast,
no significant difference was observed between Ab1–42-expressing flies
supplemented NQTrp and the control class grown on the same
medium (P.0.8). No significant difference was seen either between
the control class (males) grown on regular medium versus medium
supplemented NQTrp (P.0.5) (data not shown).
Ab1–42-expressing flies behaved normally at eclosion from the
pupal case and subsequently developed locomotion deficits as
reported [47–49]. At four days after eclosion these flies exhibited a
marked decrease (60%) in their climbing ability becoming almost
immobile by day 15, while the control classes were very active at
this time (Figure 8C). In contrast, Ab1–42-expressing flies reared on
Figure 8. NQTrp alleviates toxic effects of Ab – cell and fly
assays. A. The effect of NQTrp on cytotoxicity of soluble Ab oligmers.
Soluble oligomers were prepared with and without increasing concen-
trations of NQTrp. The cytotoxic effect of the preparations towards
cultured PC12 cells was determined using the MTT assay. Concentration
are indicated as Ab:NQTrp molar ratio. B. The effect of NQTrp on
longevity of Ab1–42-expressing flies. The life span of four classes of flies
was evaluated n= 60. Females expressing Ab1–42 grown on regular
medium (dotted line), females expressing Ab1–42 grown on medium
containing NQTrp (dashed line), males (control, carrying the Ab1–42
transgene but not expressing it) grown on medium containing NQTrp
males (control, carrying the Ab1–42 transgene but not expressing it)
grown on regular medium(not shown). C. The effect of NQTrp on
climbing behavior of Ab1–42-expressing flies.. Four classes, each
containing six vials with 10 flies in each: femalesexpressing Ab1–42
grown on regular medium (grey), females expressing Ab1–42 grown on
medium containing NQTrp (dashed line), males (control, carrying the
Ab1–42 transgene but not expressing it) grown on either regular medium
(white) or on medium containing NQTrp (black), were analyzed using the
climbing assay. Results show for each group the percent of flies climbing
to the top of the vial after 18 seconds, during the course of 14 days.
doi:10.1371/journal.pone.0011101.g008
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medium containing NQTrp displayed dramatic improvement,
behaving almost identical to the control classes (males reared on
medium lacking the compound) (Figure 8C). Importantly, no effect
of NQTrp was observed on locomotion of the control flies. One
tail ANOVA statistics showed P,0.0005 for all four classes.
To further assess the curative effect of NQTrp on AD flies, Ab
was extracted from fly brains over expressing the Arctic (Arc)
(E22G) mutant form of Ab, associated with increased aggregation
and early-onset familial AD [50]. These flies displayed short life
span and defective locomotion as reported [47] and both of these
defects were ameliorated by NQTrp as described above for Ab1–
42-expressing flies (data not shown). Aggregated forms of Ab were
readily detected in the soluble fraction of extracts from Abarc1-42-
expressing flies following immunoprecipitation with the 6E10 Ab-
specific antibody, followed by western blot. Using this procedure
monomers of Ab were detected in head extracts of both NQTrp-
fed and in non treated Abarc1-42-expressing flies. However, Ab
tetramers, which were evident in non treated Abarc1-42 flies [51],
were absent from extracts of flies fed with NQTrp (Figure 9A).
To evaluate the effect of NQTrp on Ab accumulation in the
brains of these flies, Abarc1-42 expressing larvae and adult flies, fed
or unfed with NQTrp, were immunostained with the 6E10
antibody. As reported [47,51], both the brains of untreated larvae
and adult flies displayed robust staining (Figure 9 D, E, 10 A–D)
representing accumulated Ab assemblies, not seen at all in brains
of control animals not expressing any Ab (Figure 9 A, B).
Importantly, brains of Abarc1-42-expressing animals that were fed
with NQTrp exhibited greatly reduced Ab staining. (Figure 9 F,
G, 10 E–H).
Taken together these results indicate that NQTrp reduced both
Ab oligomerization and accumulation in AD model flies.
Discussion
Our work provides a rational design route toward the
development of novel amyloid aggregation inhibitors of high
potency. The various levels of analysis indicate that indeed the
hybrid linking of naphthoquinone and tryptophan moieties leads
to a highly potent inhibitor of both the oligomerization and
fibrillization of Ab with a high affinity of 90 nM and an IC50 of
50 nM, which is markedly lower than that reported for other
aromatic Ab inhibitors (Table S6, Supp. references S1).
Our initial hypothesis that NQTrp should interact with the
central diphenylalanine recognition motif has gained direct
evidence by NMR spectroscopy and in silico analysis. The largest
chemical shift deviation was observed with Phe20 (8 Hz). A large
chemical shift deviation was also observed with Ala21 and Glu22,
5 and 3 Hz, respectively. These three sequential residues form a
turn in the NMR-derived conformers. The electrostatic potential
of the NMR conformers suggests that peptide association may be
mediated by electrostatic interactions among the distinct positive
and negative regions. Interactions between the Phe19-Phe20
aromatic side chains and NQTrp may interfere with peptide-
association.
This observation is further supported by the results of molecular
dynamics simulations which indicate that NQTrp is involved in
stable hydrogen bonds most frequently with the Phe20, Ala21 and
Glu22 backbone polar groups. Remarkably, both NMR spectros-
copy and computer simulations provide evidence that NQTrp
binds stronger to the backbone polar groups of Phe20 than Phe19,
as shown by the cluster representatives reported in Figure 7. The
van der Waals interaction analysis (Figure 6) revealed favourable
interaction energies between NQTrp and both the Phe19 and
Phe20 side chains. In fact, when NQTrp is involved in hydrogen
bonds with the backbone of the Phe20-Glu22 region, the
naphthoquinone and the indole ring are able to ‘‘clamp’’ the
phenyl ring of either Phe19 or Phe20, as shown in three of the four
most frequent binding modes (Figure 7). For geometrical reasons,
NQTrp does not frequently bind to the Phe19 backbone. As
revealed by visual inspection of the trajectories, in this conforma-
tion NQTrp ‘‘clamps’’ side chain of Val18 and the resulting
interaction is not favourable enough to stabilize this binding mode.
In addition to NQTrp a series of twelve quinone derivatives were
screened. The main result is that a hybrid between quinone and
indole is needed for optimal inhibition of both oligomerization and
fibril formation. As observed in the simulations, and in agreement
with the experimental inhibition assays, the presence of an electron-
deficient naphthoquinone moiety, together with the electron-dense
indole ring leads to the formation of a stable complex with the side
chains of Phe19 and Phe20. An essential element of the active
compounds (IL, IID, and III) is the presence of a three or four
rotatable bonds aliphatic linker between the two aromatic moieties.
Compounds with planar aromatic rings but devoid of the
aliphatic linker (molecules IV–XIII, Figure S1, Table S1) are more
rigid and for this structural reason their ability of inhibiting
oligomer formation is reduced.
Nevertheless, several of the molecules inactive against the
oligomers are still able to inhibit the fibril formation, probably
because of their ability to intercalate between the exposed side-
chains [52,53].
The main difference between IL, IID and III is the presence of a
negatively charged group (only in IL, IID) which can influence the
physical-chemical properties, e.g., the solubility andmodify their ability
of interacting with oligomers or fibrils. In addition, the most frequent
hydrogen bonds with the peptide backbone of Ab involve the quinonic
carbonyls moieties, the anilinic nitrogen and the carboxyl group of
NQTrp (Figure S4, Tables S4 and S5). Taken together these
observations could explain the difference in activity of NQTrp and
its decarboxylated analogue (molecule III, Figure S1, Table S1).
CD analysis shows a reduction in b-sheet conformation when
increasing concentrations of NQTrp are titrated into the oligomeric
‘‘ordered’’ form of Ab. In silico analysis is in accordance with these
results (Figure 5). Molecular dynamics simulations revealed that
NQTrp destabilizes the inter-chain backbone hydrogen bonds and
increases considerably the structural disorder within the Ab
oligomer. Importantly, the inhibitory effects of the tryptophan-
modified naphthoquinone on Ab assembly in vitro correlate well with
its effects in vivo. NQTrp reduced the toxicity of Ab oligomers
towards cultured cells and completely alleviated Ab-engendered
symptoms in a transgenic fly model of AD, which correlated with
reduction of both Ab oligomerization (Figure 9A) and accumulation
of Ab in the brains of these animals (Figure 9 B–G, 10 A–H).
Taken together, the results presented here for a tryptophan-
modified naphthoquinone and our comparable results with D-
tryptophan-Aib dipeptides [31] indicate that the targeting of the
central recognition interface of Ab by structural clamping and
inhibition of further oligomerization is a promising approach for
the inhibition of amyloid pathology in vivo. The unique properties
of NQTrp and its remarkable activity in vitro and in vivo make it a
promising lead for the development of small molecule inhibitors of
oligomerization for the treatment of AD.
Materials and Methods
Compounds
1,4-naphthoquinon-2-yl-L-tryptophan (NQTrp) was synthe-
sized from L-tryptophan and 1,4-naphthoquione by a one step
synthesis according to the protocol by Shrestha-Dawadi et al. [39].
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1H-NMR (DMSO-d6): d=3.3 (m, CH2), 3.9 (m, CH2), 5.6 (s,1H),
6.8 (t, J=3.3Hz, 1H), 6.8 (t, J=7.4Hz,1H), 7.1 (s, 1H), 7.2 (br m,
NH), 7.3 (d, J=8.0 Hz, 1H), 7.4 (d, J = 7.5 Hz, 1H), 7.6–7.9 (m,
4H), 10.8 (NH). Reverse phase HPLC showed .95% purity.
Synthetic Ab1–42, Ab1–40 and Ab12–28 were purchased from
Bachem, (Bubendorf, Switzerland).
Figure 9. Effect of NQTrp on Ab in larvae brains. A. Head extract from 6 days old Abarc1-42-expressing flies unfed (left) and fed (right) with
0.75 mg/mL NQTrp (N= 25 in each group). Accumulation of Ab tetramers is evident only in Abarc1-42 flies which were not fed with NQTrp. (B–G)
Immuno-staining of 3rd instar larval brains with specific Ab antibody 6E10. (B, C) Control animals not expressing any Ab (elav-GAL4/+; +/+). (D, E)
Abarc1-42-expressing animals fed with regular fly food. (F, G) Abarc1-42-expressing animals fed with NQTrp (elav-GAL4/+; UAS-Abarc1-42/+). N = 10 for
each class examined. HB – hemi-brain; VNC – ventral nerve cord. Arrows indicate Ab accumulation.
doi:10.1371/journal.pone.0011101.g009
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Determination of soluble oligomer formation
Ab intermediates and toxic oligomers were produced according
to Barghorn and coworkers [15]. To avoid pre-aggregation,
synthetic lyophilized Ab1–42 was pretreated with HFIP. Ab1–42 was
dissolved in 100% HFIP, sonicated for 20 seconds and incubated
for 2 hours at 37uC under shaking at 100 RPM. NQTrp was
dissolved in DMSO to a concentration of 30 mM, sonicated for
1 min and then diluted with DMSO to its final concentrations.
After evaporation in a speedVac, Ab1–42 was resuspended in
DMSO (with or without NQTrp) to 5 mM and diluted with
20 mM NaH2PO4, 140 mM NaCl, pH 7.4 to a final concentra-
tion of 400 mM and 1/10 volume 2% SDS (final concentration of
0.2%). The toxic Ab oligomers were generated by further dilution
with two volumes of H2O and incubated for additional 18 hours
or more (for the toxic oligomer stability assay). Ab aggregation
products were then separated using a 15% tris-tricine gel and
stained using Imperial protein stain.
Fluorescence anisotropy studies
NQTrp was dissolved in DMSO to a concentration of 50 nM
and sonicated for 5 min. The solution was immediately mixed
with aliquots of an Ab1–42 intermediate (as described above) stock
solution (20 mM) to varying final polypeptide concentrations.
NQTrp polarization measurements were carried out using an ISS
K2 fluorimeter. The solutions were excited at 280 nm and
emission was monitored at 350 nm. For each single point, at least
five measurements were collected and their average values were
used for the calculation. All experiments were performed in
phosphate-buffered saline, PBS [100 mM NaCl (pH 7.4)].
ThT kinetic binding fluorescence
Synthetic lyophilized Ab1–40 was dissolved in DMSO to a
concentration of 100 mM and sonicated for 1 min to prevent pre-
aggregation. Ab solutions were prepared by immediate dilution
with 10 mM PBS [100 mM NaCl and 0.5 mM EDTA (pH 7.4)]
to a final concentration of 10 mM [containing 10% (v/v) DMSO].
The samples were diluted again to a final concentration of 5mM
with the appropriate inhibitor concentration or with PBS for
control samples. The samples were incubated at 37uC, and the
rate of fibril formation was monitored using ThT fluorescence
analysis over the course of 270 hours. The respective excitation
and emission wavelengths were 450 nm (2.5 nm slit) and 480 nm
(5 nm slit), respectively. A 10-fold diluted sample was taken and
mixed with 900 mL of 0.4 mMThT. The fluorescence of ThT was
measured using a Jobin Yvon Horiba Fluoromax 3 fluorimeter.
Each experiment was repeated in quadruplicates.
IC50 ThT measurements
Synthetic lyophilized Ab1–42 was dissolved in DMSO to a
concentration of 100 mM and sonicated for 1 min to prevent pre-
aggregation. Ab solutions were prepared by immediate dilution
with 10 mM PBS. The samples were again diluted to a final
concentration of 5 mM with the appropriate inhibitor concentra-
tion or with PBS for control samples. ThT fluorescence was
measured after 24 hours. The respective excitation and emission
wavelengths were 450 nm (2.5 nm slit) and 480 nm (5 nm slit). A
10-fold diluted sample was taken and mixed with 900 mL of
0.4 mM ThT. The fluorescence of ThT was measured using a
Jobin Yvon Horiba Fluoromax 3 fluorimeter. Each experiment
was repeated in quadruplicates.
Transmission electron microscopy
Samples of Ab were taken after 7 days and at the end of the
ThT kinetic experiment and placed on a 400 mesh copper grid
covered by carbon-stabilized Formvar film (SPI Supplies, West
Chester, PA). The sample was allowed to stand for 1.5 min, excess
fluid was removed and the grids were negatively stained for 2 min
with 10 mL of a 2% uranyl acetate solution. Excess fluid was
removed, and the samples were viewed using a JEOL 1200EX
electron microscope operating at 80 kV.
NMR Analysis
Sample preparation. 1.06 mg of lyophilized Ab12–28 [was
dissolved in d6-DMSO to which TDW with 0.02% w/v NaN3
Figure 10. Effect of NQTrp on Ab in drosophila brains. Immuno-staining of two-day old adult fly brains with specific Ab antibody 6E10. (A–D)
Abarc1-42-expressing animals fed with regular fly food (elav-GAL4/+; UAS-Abarc1-42/+). (C, D) Enlarged images of the boxed region. (E–H) Abarc1-42-
expressing animals fed with NQTrp (elav-GAL4/+; UAS-Abarc1-42/+) (G, H) Enlarged images of the boxed region. N= 6 for each class examined.
doi:10.1371/journal.pone.0011101.g010
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was added to obtain a final sample of 1.13 mM peptide in 20%
d6-DMSO solution. The order of dissolving the peptide is essential
to achieve solubility.
NMR measurement. NQTrp was titrated into the Ab12–28
sample in 10 mL aliquots in the same solvent batch as the peptide
samples to achieve increments of 0.11 mM of NQTrp
concentration per aliquot. After each addition the 1H-NMR
spectrum was taken at 600 MHz with 16 scans at 21uC. Chemical
shift assignment was taken from [31]; K16 and G25 were
unresolved in the one-dimensional spectrum (designated by an
asterisk in Fig 3A). The difference between each amide proton
chemical shift and that of the peptide in the presence of with
0.1 mM NQTrp was determined for each subsequent aliquot.
This value was chosen to see the effect of increasing NQTrp
concentration.
Structural studies were done on the final sample from the above
under the same conditions. NMR experiments were performed on
a Bruker Avance 600 MHz DMX spectrometer operating at the
proton frequency of 600.13 MHz, using a 5-mm selective probe
equipped with a self-shielded xyz-gradient coil. The transmitter
frequency was set on the hydrogen-deuterium exchange in water
signal, which was calibrated at 4.811 ppm. Correlation spectros-
copy (COSY) [54], total correlation spectroscopy (TOCSY), using
the MLEV-17 pulse scheme for the spin lock [55], and nuclear
Overhauser effect spectroscopy [56] experiments were acquired
under identical conditions for all samples, using gradients for water
saturation. The nuclear Overhauser effect spectroscopy experi-
ments were acquired with a mixing time of 200 ms.
Spectra were processed and analyzed with the XWINNMR
(Bruker Analytische Messtechnik GmbH) and SPARKY3 soft-
ware. Resonance assignment followed the sequential assignment
methodology developed by Wu¨thrich [57]. Stereospecificity was
introduced according to the set which gave the lowest energies and
RMSDs.
Electrostatic free energies were derived from finite difference
solutions of the Poisson-Boltzman equation using the DelPhi
program [58]. The AMBER forcefield [59] was employed and a
full Coulombic calculation was performed. The positive and
negative 2 kT/e isopotential surfaces were presented using [60].
CD analysis
To avoid pre-aggregation, synthetic lyophilized Ab1–42 was
pretreated with HFIP. Ab1–42 was dissolved in 100% HFIP,
sonicated for 20 seconds and incubated for 2 hours at 37uC under
shaking at 100 RPM. NQTrp was dissolved in DMSO to a
concentration of 30 mM, sonicated for 1 min and then diluted
with H20 to its final concentrations. After evaporation in a
speedVac, Ab1–42 was resuspended in H20 (with or without
NQTrp) to 5 mM and diluted with 20 mM NaH2PO4, 140 mM
NaCl, pH 7.4 to a final concentration of 400 mM and 1/10
volume 2% SDS (final concentration of 0.2%). The toxic Ab
oligomers were generated by further dilution with two volumes of
H2O and incubated for additional 18 hours or more (for the toxic
oligomer stability assay). CD measurements were conducted using
quartz cuvette 0.1 mm path length, at 25uC, using AVIV 202 CD
spectrometer.
Simulation protocol and analysis
The molecular dynamics simulations were performed with the
CHARMM program [61,62]. The peptides and compound were
modeled using the united atoms CHARMM PARAM19 force
field with its default truncation scheme for nonbonding interac-
tions (cutoff of 7.5 A˚). Hydration effects were accounted for by
using SASA, a solvent-accessible surface based implicit model
[63]. Partial charges for NQTrp were computed with the modified
partial equalization of orbital electronegativity algorithm
(MPEOE) [64,65]. The simulation box was prepared using the
same protocol of Convertino et al. [39], having three mono-
dispersed replicas of the same heptapeptide with or without the
presence of a single NQTrp molecule. The concentration ratio
peptide:compound was 3:1. Simulations were carried out with
periodic boundary conditions at fixed peptide concentration of
5 mg/ml (the simulation box side was set to 98, 96 and 95 A˚ for
Ab14–20, Ab16–22, and Ab18–24, respectively), using Langevin
integrator at low friction constant (0.15 ps) and at a temperature
of 330 K, which yields reversible aggregation within a reasonable
computational time. For each system, ten indipendent MD runs
out of 2.5 ms each were carried out using different random number
generators for the assignment of the velocities. A 2.5 ms run takes
three weeks on a single AMD Opteron 252 CPU at 2.6 GHz.
Order parameters are useful quantities to monitor the structural
transition within peptide oligomers [46]. In particular, the nematic
order parameter allows one to measure the amount of ordered b-
structure in the system:
P2~
1
N
XN
i~1
3
2
(z^i:d^)
2
{
1
2
The unit vector d^, that defines a preferential direction, is the
eigenvector of the order matrix that corresponds to the largest
positive eigenvalue. The N molecular unit vectors z^i are built
joining the Ca atom of residue i to the Ca atom of residue i+2
(N=367). The values, ranging from zero to one, correspond to
complete disorder and complete order respectively. The complete
order is achieved when all the unit vectors are parallel or
antiparallel, while the disorder is obtained when none of unit
vectors is parallel to any of the others.
The threshold P2
* is a value of the order parameter chosen such
that it separates the ordered from the disordered phase, and was
chosen as P2
*=0.665 [39]. Thus, the order-disorder ratio r is
defined by the number of events where the system has a nematic
order parameter lower than P2
* (disorder) and greater that
P2
*(order):
r~
n(P2wP2)
n(P2vP2)
ð1Þ
Furthermore, the interference of NQTrp is measured by
calculating the inter-peptide interaction energy, which is the
CHARMM non-bond energy (van der Waals plus electrostatics) of
a given peptide with the other two, without considering the
interactions with NQTrp (Figure 5). The van der Waals
interactions between NQTrp and individual Ab residues
(Figure 6) are estimated by averaging over all trajectories and
neglecting the snapshots in which the interaction with all residues
is zero. The criteria for hydrogen bond are the H-O distance
smaller than 2.5 A˚ and a NH-O angle larger than 130 degrees.
Correlation between hydrogen bond pairs is calculated using
the following formula:
Cij~
1
T
X
t
di(t)dj(t)
where i and j are hydrogen bond indexes, T is the total number of
frames in the simulation, and is one when the hydrogen bond i is
formed at time t, and zero otherwise.
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The binding modes depicted in Figure 6 were determined by
selecting the simultaneous and most frequent hydrogen bonds
between the peptide backbone and NQTrp (see Table S4). Single
peptide conformations that interact with NQTrp through the
selected hydrogen bonds were extracted. Resulting snapshots were
clustered by using an algorithm from Dr. M. Scha¨fer (Michael
Scha¨fer, Syngenta Crop Protection AG, unpublished work) with a
cutoff of 1.5 A˚ and selecting peptide heavy atoms close to NQTrp
and excluding symmetrical atoms.
Cell cytotoxicity assays
PC12 neuronal cells (26105 cells/mL) were cultured in 96-well
micro plates (100 mL/well) and incubated overnight at 37uC. To
each well we added 100 mL of 5 mM Ab toxic oligomers and
inhibitors at various concentrations. Each experiment was
repeated four times. Following incubation for 24 hours at 37uC,
cell viability was evaluated using the MTT assay. Briefly, 20 mL of
5 mg/mL MTT dissolved in PBS were added to each well. After
4 hours of incubation at 37uC, 100 mL of extraction buffer [20%
SDS dissolved in a solution of 50% dimethylformamide and 50%
DDW (pH 4.7)] were added to each well, and the plates were
incubated again overnight at 37uC. Finally, color intensity was
measured using an ELISA reader at 570 nm.
Fly keeping
Flies were reared on standard corneal-molasses medium and
were kept at 25uC. As Drosophila females can store sperm cells in
their bodies, crosses were conducted using virgin females collected
no longer than 8 hours after eclosion at 25uC or 18 hours after
eclosion at 18uC. Adult offspring (F1) from the crosses were
collected up to 9 days after the beginning of their eclosion at 25uC
in order to avoid offspring from the next generation (F2).
Fly crossing
Male flies carrying the driver elavc155-Gal4 (on their X
chromosome) were crossed to females carrying the Ab1–42
transgene (located on an autosome) under the UAS promoter in
a homozygous condition. This resulted in first generation (F1)
female offspring expressing Ab1–42 in their nervous system. They
served as our Alzheimer’s Drosophila model. Male F1 offspring,
which carried the Ab1–42 trasgene but did not express it (because
they lacked the Gal4 driver) served as a control. Animals
expressing Abarc1-42 were generated in a similar way.
Fly feeding
NQTrp was added to standard corneal-molasses medium about
10 minutes after cooking (0.75 mg/mL). The compound was mixed
thoroughly into the medium and the mixture was aliquoted into
rearing vials. The vials were kept at 4uC until use. Crosses were
performed either on regular Drosophila medium (control) or on
medium supplemented with NQTrp. Animals fed on the appropri-
ate medium from the beginning of the larval stage onwards. Animals
expressing Abarc1-42 were generated and assayed in a similar way.
Longetivity assay
Flies expressing one copy of Ab1–42 reared at 29uC on medium
with and without NQTrp were classified into four classes: 1.
Females expressing Ab1–42, on regular medium. 2. Females
expressing Ab1–42, on medium supplemented with NQTrp. 3.
Male controls (lacking the Gal4 driver), on regular medium. 4.
Male controls (lacking the Gal4 driver), on medium supplemented
with NQTrp. For each class, six vials each with 10 flies were
collected and fresh food was provided every three days (whether
with or without NQTrp). The number of viable Ab-expressing and
control flies treated with and without NQTrp was recorded daily
post eclosion. Differences in survival rates were analyzed using the
SPSS 11 Kaplan-Meir software package. Animals expressing
Abarc1-42 were generated and assayed in a similar way. The
longetivity assay was repeated three times. All three analyses
showed similar results.
Locomotive (climbing) assay
Test tubes of each of the four classes mentioned above, each
containing 10 flies, were tapped gently on the table and were let
stand for 18 seconds. The percent of flies which climbed to the top
of the test tube was then calculated over time [50,51]. Each class
had six independent vial-repeats. Statistical analysis was done
using StatSoft Statistica 7, parametric ANOVA testing. The
locomotive assay was repeated three times. All three analysis
showed similar results.
Immuno-precipitation and western-blot of fly head
extracts
Twenty five freshly decapitated heads from 6 day old Abarc1-42
flies treated and non-treated with NQTrp were collected and
homogenized in 30 ml PBS/protease inhibitor/ 1% SDS following
[46]. Homogenates were then centrifuged at 13000 rpm for
25 seconds and the supernatant was further immuno-precipitated
with specific 6E10 anti-Ab antibody (1:10) over night at 4uC.
Boiled samples were then western blotted and membranes were
boiled in PBS for 10 minutes before antibodies were introduced.
Total protein levels of the samples were quantified using Bradford
analysis prior to gel loading. Since samples were loaded after IP
with specific 6E10 anti-Ab antibody, no marker protein levels
could be measured.
Immuno-staining of larval brains
3rd instar larvae were dissected and stained using the following
antibodies: primary 6E10 antibody (1:250) and secondary
biotinylated anti-mouse antibody detected with Vecta-Stain-Elite
ABC-HRP kit (Vector Laboratories). Stained larvae brains were
mounted in 70% glycerol, 30% Tris pH 7.6 and viewed using
bright-field microscopy (Nikon, Eclipse E600).
Immuno-staining of adult fly brains
Two-day old adult flies were dissected and their brains were
removed. Whole brains were stained using the following
antibodies: primary 6E10 antibody (1:250) and secondary anti-
mouse Cy3 (1:100). Stained whole brains were imaged using
confocal microscopy (LSM 510).
Supporting Information
Figure S1 Structure of naphthoquione-based molecules
screened for inhibition of Ab assembly. Compounds IL and IID
are L and D isomers of NQTrp.
Found at: doi:10.1371/journal.pone.0011101.s001 (0.04 MB
DOC)
Figure S2 1H-NMR spectra. Fingerprint regions of TOCSY
(greens) spectrum overlaid on NOESY (reds) spectrum of Ab12–28
with NQTrp (4:1 molar ratio) with assignment.
Found at: doi:10.1371/journal.pone.0011101.s002 (0.23 MB
DOC)
Figure S3 1H-NMR derived structures. Ensemble of nine low
energy structures generated for Ab12–28 with NQTrp (4:1 molar
ratio).
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Found at: doi:10.1371/journal.pone.0011101.s003 (0.08 MB
DOC)
Figure S4 Hydrogen bonds frequency between NQTrp and Ab
peptide backbone: For polar group labeling refer to the inset of
Figure 5.
Found at: doi:10.1371/journal.pone.0011101.s004 (0.05 MB
DOC)
Figure S5 Cytotoxicity analysis of NQTrp: PC12 cell line was
incubated with different concentrations of NQTrp. The cytotoxic
effect of NQTrp was determined using the MTT assay. Control -
no NQTrp.
Found at: doi:10.1371/journal.pone.0011101.s005 (0.03 MB
DOC)
Table S1 Summary of Ab inhibition by all molecules examined:
Twelve naphthoquione-based molecules were analyzed for
inhibition of both oligomer and fibril formation. The relative
degree of inhibition is indicated. No inhibition (2), low inhibition
(+), moderate inhibition (++), significant inhibition (+++).
Found at: doi:10.1371/journal.pone.0011101.s006 (0.03 MB
DOC)
Table S2 Neo constraints.
Found at: doi:10.1371/journal.pone.0011101.s007 (0.05 MB
DOC)
Table S3 Average number of hydrogen bonds: aAverage
number of inter- and intra-peptide backbone-backbone hydrogen
bonds, with (+) and without (2) NQTrp. The standard deviation is
evaluated on ten independent simulations. bRatio between order
and disorder events sampled in the simulations.
Found at: doi:10.1371/journal.pone.0011101.s008 (0.05 MB
DOC)
Table S4 Hydrogen bond correlations: Correlation among pair
of hydrogen bonds between individual polar groups of NQTrp
and the peptide backbone. The pairs occurring more frequently
are reported in bold. The naming convention of the polar groups
of NQTrp is as Fig. 6.
Found at: doi:10.1371/journal.pone.0011101.s009 (0.11 MB
DOC)
Table S5 Highest probability hydrogen bonds: Pairs of hydro-
gen bonds with the highest probability (.0.01) to be simulta-
neously formed. The naming convention of the polar groups of
NQTrp is as Fig. 2 bottom.
Found at: doi:10.1371/journal.pone.0011101.s010 (0.06 MB
DOC)
Table S6 IC50 of aromatic inhibitors of Ab.
Found at: doi:10.1371/journal.pone.0011101.s011 (0.03 MB
DOC)
References S1 References for table S6.
Found at: doi:10.1371/journal.pone.0011101.s012 (0.02 MB
DOC)
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Chapter 4 
 
A!12-28 conformational change  
induced by small molecules 
 
 
 
The present project was defined in follow-up to the results of the fruitful 
collaborations with the labs of Prof. E. Gazit and Prof. A. Carotti presented 
herein in previous chapters. Implicit solvent MD simulations were 
employed to further investigate the interactions between two small-
molecules, which were identified as A! aggregation inhibitors (1,4-
naphtoquinon-2-yl-L-tryptophan and 9,10-anthraquinone, here reported as 
NQTrp[48] and AQ[49], respectively) during our previous studies, and the 
central amino acid sequence of the !-amyloid peptide (A!12-28). MD results 
suggest that both NQTrp and AQ play an important role in promoting a 
conformational change in A!12-28, inducing the formation of a collapsed 
loop, thus creating a binding pocket with which NQTrp and AQ can interact 
via hydrogen bonds, electrostatic and van der Waals interactions. 
 
 
4.1 Simulations setup 
 
Langevin MD simulations of the highly aggregation-prone capped A!12-28 
segment were undertaken both alone and in presence of a single NQTrp or 
AQ molecule (molecular structures are represented in Figure 2 of the 
Introduction), at a temperature of 300 K, with an inhibitor concentration of 
5 mg/ml and under periodic boundary conditions. Multi-microseconds 
(3x5µs) simulations were performed using the united atom (param19) 
CHARMM[78,79] force field and FACTS[89] implicit solvent model. 
The cut-based Free Energy Profile (cFEP) approach[101] (see Introduction 
for further details) was used to study the free-energy landscape of A!12-28, 
and thus, to isolate energetic basins of kinetically closed conformational 
states, as well to identify potential NQTrp and AQ binding modes. 
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4.2 Variation of A!12-28 secondary structure propensity 
 
Among numerous analyses of the simulated systems, the present project 
issued from calculations of the secondary structure propensity (computed 
using the sstruct module in WORDOM[107]) of A!12-28 alone and in 
presence of inhibitor molecules in equimolar concentration. Both NQTrp or 
AQ induce a variation in the secondary structure propensity along the amino 
acid sequence of A!12-28. These inhibitors reduce the helical propensity of 
this peptide, particularly along the V12-D23  segment. 
 
 
 
!
Figure 1. Variation of A!12-28 secondary structure propensity in presence of NQTrp or AQ. 
!
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4.3 Isolation of conformational basins 
 
Based on the results of the above described analysis, a more in-depth 
investigation of the conformational changes induced by the presence of 
NQTrp and AQ was undertaken using the cFEP approach[101] to study the 
free-energy landscape of A!12-28, and thus, to isolate energetic basins of 
kinetically closed conformational states of A!12-28 alone and in presence of 
NQTrp or AQ. 
 
 
4.3.1 cFEP analysis of the MD trajectory of A!12-28  
 
The set of network nodes of the MD-generated conformations, derived by 
clustering the simulation snapshots according to user-defined metrics, 
serves as input for cFEP profile determinations. In the present study, a 
cluster analysis based on C"(H14-S26)-RMSD was performed over the entire 
15µs trajectory using the LEADER algorithm as implemented in 
WORDOM[107].  
As the first and last two residues forming the N- and C-terminus, 
respectively, were highly mobile throughout the simulations, these residues 
were discarded in order to reduce excessive noise in the data.  
Three cFEP curves were derived starting from different initial clusters 
(obtained using 1.5 , 1.8 , 2.0  cutoff values, Figure 2a). All three cFEP 
profiles clearly indicate the presence of an energetic basin accounting for 
about 10% of the full conformational space.  
In order to identify the representative conformations of the isolated  
energetic basins, the MD time-series was rearranged according to the ZA/Z 
progress coordinate into a new time-independent trajectory; A!12-28 
secondary structure (Figure 2b) and radius of gyration (Figure 2c), as well 
as C"-RMSD with respect to the representive of the most populated node of 
A!12-28 alone (Figure 2d) and in presence of NQTrp (Figure 2e) were 
calculated. As shown in Figure 2 (b-e), the first basin is characterized by the 
presence of A!12-28 in helical conformation (Figure 5, left). This basin is 
separated from a basin corresponding to a collapsed loop conformation, 
which accounts for about 2% of the full conformational space (0.94 ! ZA/Z 
! 0.96), by a large entropic basin of extended random-coil structures. 
 
! &'!
!
Figure 2. cFEP analysis of A!12-28 alone. a) cFEP curves obtained using the C"(H14-S26)-RMSD 
clustering with 1.5 (black), 1.8  (red) and 2.0  (green) cutoff starting from the most populated 
node; nodes are ranked according to their mfpt values. b) Secondary structure analysis for the full 
time-series rearranged according to the ZA/Z progress coordinate. c) Radius of gyration along the 
ZA/Z-rearranged trajectory. d) C"-RMSD computed along the ZA/Z-rearranged trajectory with 
respect to the representative of the most populated node of A!12-28 alone and e) in presence of NQTrp. 
Diffusivity test plots can be found in the Appendix sections. 
 
 
 
4.3.2 cFEP analysis of A!12-28 trajectories in presence of NQTrp 
or AQ 
 
The same set of analyses was performed for A!12-28 in presence of a single 
molecule of NQTrp or AQ, using the already cited settings for the A!12-28 
system. As expected, the cFEP curves show a different profile with respect 
to the one retrieved for A!12-28 alone.  
In the two ÔinhibitedÕ systems (i.e., A! simulated in presence of an inhibitor 
molecule), the first basin corresponds to a collapsed loop conformation 
(Figure 5, right) covering about 22% and 10% of the conformational space 
for NQTrp and AQ, respectively. In both the A!12-28/NQTrp and A!12-28/AQ 
systems, this basin is separated from a second one, corresponding to a 
helical conformational state, by a large entropic basin of extend random coil 
conformations (Figures 3 and 4). 
!
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Figure 3. cFEP analysis of A!12-28 in presence of NQTrp. a-c) Same as Figure 2 for NQTrp. d) C"-
RMSD computed along the ZA/Z-rearranged trajectory with respect to the representative of the most 
populated node of A!12-28 in presence of NQTrp and e) alone. Diffusivity test plots in the Appendix. 
 
!
!
Figure 4.!cFEP analysis for A!12-28 in presence of AQ. a-c) Same as Figure 2 for AQ. d) C"-RMSD 
computed along the ZA/Z-rearranged trajectory with respect to the representative of the most 
populated node of A!12-28 in presence of AQ or e) NQTrp. 
! &)!
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Figure 5. (Left) Representative conformations of the 1st basin indentified by the cFEP for the A!12-28 
monomer alone (statistical weight 10% of the conformational space). (Right) Conformations of the 
1st basin indentified by cFEP in presence of NQTrp or AQ (statistical weight 22% and 10% of the 
conformational space for NQTrp and AQ, respectively). Representative structures are plotted 
skipping each 1000 conformations and fitting over the sequence Q15-F20 C"; the blue and red spheres 
indicate the N- and C-terminus, respectively.  
 
 
 
4.4 Potential A!12-28 binding modes of NQTrp and AQ  
 
The generated cFEP profiles revealed that the formation of a collapsed loop 
conformation of amyloid peptide is increased from about 2% in the case of 
A!12-28 alone to about 22% or 10% in presence of NQTrp or AQ, 
respectively.  
The analyses of the intermolecular distances between A!12-28 and NQTrp or 
AQ pointed out that the former inhibitor is more tightly bound to A!12-28 
than the latter; in particular, for both NQTrp and AQ, the statistical weight 
of the bound state is about 10% higher in the first cFEP basin (see Table 1 
in Appendix and figure 6) from which the A!12-28 collapsed loop 
conformations were identified.  
All snapshots belonging to the first basin of A!12-28/NQTrp and A!12-28/AQ 
were isolated and a second cFEP analysis was performed, clustering the 
snapshots according to the (H14-Q15-K15)/NQTrp or to the (H14-Q15-K16)-AQ 
DRMS with a cutoff of 1.0  (see Figures A3-A6 in the Appendix). 
These three A! amino acids were selected  as their interaction energies were 
the most favourable as computed by CHARMM and as they formed a high 
number of hydrogen bonds with NQTrp and AQ over the full trajectory (see 
! &*!
Figures A7 and A8 in the Appendix). All of the snapshots of the first basin 
obtained with the second cFEP analysis (covering about 7% and 4% of the 
selected conformational space of A!12-28/NQTrp and A!12-28/AQ, 
respectively) were isolated and one of the possible NQTrp and AQ binding 
modes was identified. 
The NQTrp and AQ atomic distributions around A!12-28 within the first 
basin of the DRMS-based-cFEP profile, as well as the representatives of the 
most populated nodes (about 2% and 1% of the selected conformational 
space for NQTrp and AQ, respectively) are represented in Figure 7. 
 
!
Figure 6. Intermolecular distances between A!12-28 and NQTrp (top) or AQ (bottom). For each of 
the two systems all snapshots belonging to the 1st cFEP basin were isolated from the other snapshots 
of the simulations; for the resulting two subsets, the minimum all-atom distance between the inhibitor 
and A!12-28, the distance of their centers of mass, and the contact efficiency (number of 
contacts/number of heavy atoms in the inhibitor, distance-cutoff set at 4.0 ) were computed.!
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Figure 7. (a, left) NQTrp quinonic oxigens (red), carboxylic carbon (magenta) and indolic nitrose 
(blue) distributions within 3.5  from A!12-28 are symbolized as spheres (DRMS-based-cFEP 1
st 
basin, denser clouds indicate a higher coordination); (a, right) representative structure of the most 
populated node indicating one of the possible NQTrp binding mode. (b, left) AQ quinonic oxigen 
(red) distribution within 3.5  from A!12-28 is symbolized as spheres (DRMS-based-cFEP 1
st basin, 
denser clouds indicate a higher coordination); (b, right) representative structure of the most 
populated node indicating one of the possible AQ binding mode. 
!
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4.5 Comparison between NMR- and MD-derived NOE 
 
The NOE distance r(t) (i.e., the inter-proton distance at simulation time t) 
was calculated along 15 µs of MD sampling of a 1:1 system of A!12-28 and 
NQTrp. The NOE upper distance limits were derived from MD simulations 
using the formula <r(t)-6>-1/6 as suggested by Tropp[108] for small peptides 
or molecules for which the timescale of internal fluctuations is longer than 
the overall tumbling time. The plot in Figure 8 shows that intramolecular 
NOE upper distance limits were only marginally violated (seven statistically 
significant violations over twentyfive). 
 
 
4.6 Conclusions 
 
A detailed description of the interactions between selected aggregation 
inhibitors and the A!12-28 monomer was obtained using implicit solvent MD 
simulations.  
The presence of NQTrp or AQ was found to induce a conformational 
change over the A!12-28 sequence, from a helix to a collapsed loop, that 
creates a binding pocket with which inhibitors molecules can interact.  
In silico results are supported by NMR data; indeed, NOE long-range 
intermolecular upper distance limits were only marginally violated. 
! &&!
 
!
Figure 8"!NMR NOE upper distance constraints (blue empty diamonds) and calculated from the MD 
runs (filled circles with dashed bars for standard deviations). The colors indicate further than i, i+3 
(black), and i, i+3 (red) NOE signals, respectively. The blue dashed line at the bottom indicates van 
der Waals distance values as they were obtained from the NMR experiment. 
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Appendix to Chapter 4 
 
 
!
Figure A1. Diffusivity test of the cFEP analysis on A!12-28 as reccomended by Krivov and 
Karplus[109]. 
!
!
Figure A2. Diffusivity test of the cFEP analysis on A!12-28 in presence of NQTrp (as in Figure A1). 
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Figure A3. cFEP profile for A!12-28 in presence of NQTrp. The cluster analysis was performed using 
(H14-Q15-K16)/NQTrp DRMS with 1.0  cutoff. The first basin covers about 7% of the selected 
conformational space. 
!
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!
Figure A4. cFEP profile for A!1228 in presence of NQTrp. The cluster analysis was performer using 
(H14-Q15-K16)/NQTrp DRMS with 1.0  cutoff. The first basin covers about 4% of the selected 
conformational space. 
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Figure A5. Diffusivity test of the DRMS-based cFEP analysis on A!12-28 in presence of NQTrp (as in 
Figure A1). 
 
 
!
Figure A6.!Diffusivity test of the DRMS-based cFEP analysis on A!12-28 in presence of AQ (as in 
Figure A1). 
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Figure A7. CHARMM interaction energies and hydrogen bond frequency between A!12-28 and 
NQTrp computed over the full trajectory. 
!
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!
Figure A8.!CHARMM interaction energies and hydrogen bond frequency between A!12-28 and AQ 
computed over the full trajectory. 
! &(!
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Table A1. Statistical weight of the bound state of NQTrp and AQ. 
conformational 
space 
cutoff () NQTrp (%) AQ (%) 
5 70 38 
6 70 38 full trajectory 
8 71 39 
5 79 41 
6 80 41 
1st basin of 
RMSD-based 
cFEP profile 
8 80 42 
5 67 37 
6 68 38 
all RMSD-based 
cFEP profile 
excluding the1st 
basin 
8 68 39 
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Chapter 5 
 
 
 
Conclusions and outlooks 
 
ÒE scoperse cosi, non senza umiliazione, 
che un piccolo ippopotamo  sempre 
un po' pi grosso di un grossissimo moscone.Ó 
G. Rodari 
 
Three research projects are presented hereabove in which molecular 
dynamics (MD) simulations provide an atomistic level description of the 
mechanisms of interference of selected low molecular weight compounds  
in !-amyloid peptide (A!) aggregation. 
First, the influence of 9,10-anthraquinone (AQ) and antracene (AC) on 
A!14-20 aggregation was studied, using the nematic order parameter P2 to 
monitor the extent of !-aggregation perturbation. Through favorable polar 
interactions with the peptide backbone, AQ was found to destabilize the 
interstrand hydrogen bond pattern of A!14-20 aggregates to a greater degree 
than AC. Specifically, the AQ quinonic moiety tightly binds the peptide 
backbone through hydrogen bonds and exa-/octupolar (herein named "
+
#
-
) 
interactions[47]. 
The property of the quinonic structure as an amyloid aggregation inhibitor, 
together with tryptophan's amyloid recognition propensity, provided a 
rational design route leading to the definition of a new hybrid molecule, 1,4-
napthoquinon-2-yl-L-tryptophan (NQTrp), whose evaluation formed the 
basis of the second project. NQTrp was found to be a highly potent inhibitor 
of A! oligomerization and fibrillization in silico; this was confirmed using a 
variety of experimental techniques, including Thioflavin T (ThT) binding 
assays, Circular Dicrohism (CD) and Transmission Electron Microscopy 
(TEM). NQTrp notably reduced the neurotoxicity due to A! 
oligomerization in the in vivo transgenic Drosophyla Melanogaster model 
(AlzhaFly)[46]. 
A more detailed description of the interactions between selected aggregation 
inhibitors and A!12-28 monomers resulted from the third project. Using the 
cut-based free-energy profile (cFEP) method[101], an inhibitor-induced 
conformational change in the form of a collapsed loop in A!12-28 was 
identified. This conformational change creates a binding pocket with which 
! "$!
inhibitor molecules can preferentially interact. 
Using the cut-based free-energy profile (cFEP) method[101], an inhibitor-
induced conformational change in the form of a collapsed loop in A!12-28 
was identified. This conformational change creates a binding pocket with 
which inhibitor molecules can preferentially interact. 
The presence of collapsed-loop A! conformations induced by quinonic 
moieties was confirmed by NMR spectroscopic techniques. Nonetheless, the 
ease of transition over the first conformational barrier (of about 1 kcal/mol) 
of the two 'inhibited' and the inhibitor-free systems, suggests that the A!12-
28 conformational change in presence of quinonic moieties plays only a 
secondary role in aggregation inhibition. Indeed, an increase in the 
aggregation lag-phase was not detected by in vitro ThT binding assays, 
though the influence of differing experimental and in silico conditions 
cannot be excluded. Rather, the proposed inhibition mechanism referring to 
the hindering of inter-peptide hydrogen bond formation between A! 
monomers is likely to be of primary relevance. 
In conclusion, the atomistic descriptions resulting from the MD simulations 
in these three studies provide a reliable starting point for the screening and 
design of small-molecule inhibitors of amyloid aggregation having 
therapeutic potential for the treatment of AlzheimerÕs disease. 
Future studies could include structure-based virtual screening (docking on 
the A!12-28 collapsed conformation) of appropriately selected chemical 
libraries in order to identify improved A! aggregation inhibitors. 
Moreover, computational and experimental evaluations of putative chimeric 
inhibitors (such as quinonic derivatives of nicotine or cotinine, or chimeric 
molecules based on the results of the proposed virtual screening) could be 
performed. Such new chemical entities might present advantageously high 
inhibitory activity towards A! aggregation, thus allowing a reduction in the 
needed dose relative to current lead compounds, thereby potentially limiting 
the risk of side-effects.!
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